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The capacity of the host to mount an effective immune response (IR) is crucial for 
the protection against invading pathogens. The apoptotic and proinflammatory responses 
of infected cells are important innate immune mechanisms. Consequently, the ability of 
persistent intracellular pathogens, such as the human pathogen Mycobacterium 
tuberculosis (Mtb), to inhibit infection-induced apoptosis of macrophages is important for 
its virulence in the host. Facultative-pathogenic mycobacterial species, like M. kansasii 
(Mkan), can cause disseminating disease in individuals with immune deficiencies. In 
contrast, non-pathogenic mycobacteria, like M. smegmatis (Msme), are not known to 
cause disseminating disease even in immunocompromised individuals. We hypothesized 
that this difference in phenotype could be explained by the strong induction of an innate 
IR by non-pathogenic mycobacteria.  
Here we analyze the mechanisms by which non-pathogenic mycobacteria induce a 
strong IR in their macrophage and dendritic cell (DC) host, specifically the induction of 
host cell apoptosis and the host inflammasome response via the secretion of IL-1β. The 
comparison of two non-pathogenic mycobacterial species (Msme and Mkan) with two 
facultative-pathogenic mycobacterial species (M.kan and M. bovis BCG) demonstrated 
that only the non-pathogenic mycobacteria induce strong apoptosis in murine bone 
marrow derived macrophages (BMDM) and dendritic cells (BMDC), which was 
dependent upon caspase-3 activation and TNF secretion. Consistently, BMDMs 
responded by secreting relatively large amounts of TNF and by upregulating the 
expression of Il-12. We also demonstrated that Msme infection of BMDCs strongly 
induces the secretion of IL-1β. This induction was dependent upon the presence of 
functional ASC and was partially independent of NLRP3. Interestingly this induction was 
also partially dependent on AIM2 and IFN-β. This AIM2-dpendent induction was 
observed in infection with non-pathogenic and opportunistic mycobacteria, and 
attenuated but not virulent Mtb. Surprisingly, caspase-1/11 deficient BMDCs still 
secreted substantial but reduced amounts of IL-1β upon Msme infection.  
In conclusion, we demonstrate a strong induction of the innate IR by non-
pathogenic mycobacteria as measured by host cell apoptosis, and IL-12 / TNF / IL-1β 
cytokine induction. We also demonstrate the partially caspase-1/11 and NLRP3 -
independent, partially AIM2-dependent, but ASC-dependent IL-1β secretion in Msme 
infected BMDCs. Our findings support the hypothesis that the strong induction of the 
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CHAPTER 1. INTRODUCTION 
1.1 Tuberculosis (TB). 
1.1.1 Tuberculosis, the disease. 
 Tuberculosis is a disease that has been in existence since antiquity causing human 
mortality for thousands of years from pre-historic era to our current day [1] [2]. In the past 
TB used to be called “consumption” and regarded as “vampirism” as one infected person in 
the family died from TB, other infected family members would become diseased and loose 
their health slowly, which was regarded as the first diseased person draining the life out of 
the rest of the family [3]. It was also called ‘consumption’ because it was perceived to 
consume people from within with a severe bloody cough, fever, and heavy wasting. TB 
remains a global health problem with ten million new cases and causing the death of more 
than two million people every year [4]. Mycobacterium tuberculosis (Mtb), the etiologic 
agent of TB, infects approximately two billion people worldwide in most parts of Africa, 
India, and parts of Eastern Europe (Figure 1) [4]. Tuberculosis manifests itself as a 
pulmonary disease with a high infection rate as it transmits via the aerosols [5], which are 
formed when a person simply coughs or sneezes. Mtb primarily infects alveolar 
macrophages in the lungs, and other phagocytic white blood cells, which provide a niche 
for the bacteria to survive, multiply, and propagate. Once infected, macrophages may die 
via necrosis and release the bacteria into the extracellular environment leading to infection 
of other macrophages and phagocytic white blood cells such as dendritic cells and 
neutrophils. During infection with Mtb, macrophages and other white blood cells are 
recruited to the site of infection where they induce an inflammatory response. The newly 
recruited and infected macrophages and white blood cells will then start forming a  


















Adapted from [6]. 
 
Figure 1. Global instances in TB in 2010 according to the World Health Organization 
(WHO). The WHO Global TB control report 2011 showing a geographical distribution of 
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granuloma at the infection site [7-10]. The granuloma consists of a core of infected 
macrophages that sometimes undergo necrosis and get surrounded by lymphocytes [7]. The 
infected macrophages release IL-12 and IL-23 to promote a Th1 lymphocyte primary 
response, which then activate the immune system by the release of interferon-γ (IFN-γ) and 
TNF [11]. These immunomodulatory signals are sensed by the immune system, which gets 
activated but fails to clear the infection. Within granulomas, Mtb can survive for decades 
without getting cleared but is unable to cause any new pathology [7] [12]. During this 
dormant phase of TB called latency, individuals do not develop any symptoms of the 
disease and are generally not contagious. However, 10% of individuals infected with Mtb 
may develop active TB when they become immunocompromised or immunosuppressed 
either from old age, malnutrition, treatment with immunosuppressant drugs, or commonly 
from infection with other pathogens such as the human immunodeficiency virus (HIV) [13-
15]. In the event where latent TB develops into active disease, the infecting bacteria induce 
necrosis and caseation within the granuloma, which results in the release of Mtb into the 
lungs tissue and airways. This invasion of lung tissues and airways often leads to the 
propagation and dissemination of the bacteria into other tissues in the body leading to 
pathology in the liver, bone, spleen, and brain [16]. The disease is contagious in individuals 
with active TB, which manifests in symptoms of consumption that include excessive cough, 
bloody mucus, fever, fatigue, night sweats, unexplained weight loss, chills, and loss of 
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1.1.2 Treatment and prevention. 
1.1.2.1 Drug therapies. 
TB existed among humans for thousands of years at times when antibiotics and 
vaccines did not exist. The best treatment for TB was thought to be bed rest, good nutrition 
and proper ventilation of the breathing environment by providing fresh air for patients [19]. 
Robert Koch, the discoverer of Mtb, proposed the first attempted medical cure for the 
disease in 1882. Koch used tuberculin, an extract from the bacterium Mtb and tried to cure 
infected individuals. His attempt failed but tuberculin is still used today for the diagnosis of 
TB infections in humans via the PPD skin test and other adjuvant drug therapies [20]. In 
1946 Albert Schatz and Selman Waksman discovered streptomycin, which was then 
adopted as the first effective drug against TB infections [21]. Other new antibiotic drugs 
were discovered in the following years including isoniazid, rifampicin, pyrazinamide, and 
ethambutol [22]. These drugs have shown to be effective since they caused a substantial 
decrease in the mortality rate due to TB associated illnesses [22]. However, there are many 
problems associated with the use of these first line antibiotics against TB. First, some of 
them can cause severe hepatotoxicity [23] [24]. Second, the course of treatment with these 
drugs is fairly long (approx. 6-9 months) which causes toxicity and socio-medical problems 
[25-27]. The prolonged treatment with the drugs puts more stress on tissues and organs and 
may lead to tissue injury, as is the case with isoniazid [24]. This fairly long treatment also 
is a socio-medical problem since infected individuals mostly reside in poor areas of the 
world and they fail to adhere to the treatment regimen for this long period of time. Failure 
to follow the precise treatment regimen leads to the emergence of drug resistant strains of 
Mtb [26]. Third, these antibiotics are unable to effectively clear bacteria that are not 
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genetically drug resistant from infected individuals as drug-susceptible bacteria are often 
found to be persistent in patients that already underwent drug therapy [25] [28]. This might 
be due the hiding of bacteria in granulomas, sequestered in tissues away from the drugs. 
Alternatively, Mtb might also adopt a physiological state inside the granuloma that renders 
them insensitive to the drugs [28]. 
 
1.1.2.2 Bacillus Calmette-Guérin (BCG) vaccine. 
 Microbiologists Albert Calmette and Camille Guérin created the first and only 
known TB vaccine called ‘BCG’ in 1908 and it has been used worldwide as a vaccine 
against TB [29] [30]. However, the vaccine’s efficacy currently ranges from zero to eighty 
percent with highest efficacy against TB infections in infants as reported in clinical trials 
[31] [32]. Initially, the BCG vaccine was created by passaging pathogenic Mycobacterium 
bovis (M. bovis) in culture for eleven years until it lost its virulence in humans. BCG was 
then shipped to different parts of the world where each country continued passaging the 
bacteria in culture to maintain their own stock [33]. The variability in the efficacy of the 
vaccine over a wide range is suggested to be due to genomic differences among the BCG 
substrains form different regions of the world [34]. This is due to the independent 
passaging of the original parent strain at various sites [31]. This difference in efficacy 
might also be due to differences in BCG-induced immunity in different populations due to 
different environmental exposures [35]. Indeed, I co-authored a study in which we 
demonstrated that different M. bovis BCG substrains from various regions of the globe 
confer different levels of protection against Mtb infections in mice. The different BCG 
substrains induced different levels of adaptive T cell immune response (IR), which we 
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demonstrated to be linked to the differences in the number of genomic regions of deletions 
(RD) among the different BCG substrains [31]. 
 
1.1.2.3 Current state of TB Infections. 
 The 20th century was marked by a decrease in the mortality rate associated with TB 
infections due to improvements in public health and general public awareness, as well as 
the discovery and use of the BCG vaccine and chemotherapeutical TB drugs [36]. Despite 
this decrease in mortalities, TB was never eradicated and still is endemic in many parts of 
the world including Africa, Southeast Asia, and Western Europe causing a global health 
threat [37] (Figure 1). The 1980s have seen a rise of drug-resistant strains of TB such as the 
increase in TB infections in Britain, which diminished all hopes that the disease could have 
been eradicated [36] [38]. The incidences of multi-drug-resistant (MDR) TB and extreme-
drug-resistant (XDR) TB have also risen resulting in the declaration of a global health 
emergency by the World Health Organization (WHO) in 1993 [38] [39]. MDR Mtb is 
resistant to at least one of the two most powerful first line drugs isoniazid and rifampicin 
[36]. XDR Mtb emerged as a consequence of chemotherapies against MDR-TB involving 
second line drugs [38]. XDR Mtb is resistant to first line drugs, fluoroquinolones, and at 
least one of the injectable drugs (amikancin, kanamycin, or capreomycin) [36-38].  
In addition, the emergence of HIV in the 1990s and the incidences of HIV-TB co-
infections especially in Africa and Asia increased the rate of mortality in TB patients [40]. 
HIV-positive patients infected with Mtb are more likely to become symptomatic and suffer 
from active TB than HIV-negative patients [41]. HIV compromises the immune system and 
causes a progressive loss of Th1 cell mediated IR, which is required to defend against Mtb 
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infections, thus making it harder for HIV-TB co-infected individuals to control Mtb 
infections [14] [15] [42]. This is a major health risk since it was shown that most HIV 
patients with XDR-TB die with a median survival time of 18 days post infection [42]. 
 
1.2 Mycobacteria. 
 Mycobacterium is a genus of bacteria that belongs to the family of 
Mycobacteriaceae and contains more than fifty well-characterized species, which vary in 
their environmental niches, their physical growth, and their ability to cause disease in 
different hosts [43] [44]. They are intracellular, rod-shaped, aerobic, Gram-positive bacilli 
known for their thick cell walls rich with lipids and unique mycolic acids. They retain the 
carbol fuchsin dye in the presence of acidic alcohol in an acid fast staining [45]. Species in 
the mycobacterium genus are classified into three main groups for the purpose of diagnosis 
and treatment: Mycobacterium tuberculosis complex (MTBC), Mycobacterium leprae, and 
nontuberculous mycobacteria (NTM).  
The Mycobacterium tuberculosis complex (MTBC) is a group of phylogenetically 
closely related sub-species sharing more than 99% identity at the nucleotide level for some 
loci and are known to cause TB in human and diverse animal hosts. These include the 
human pathogens Mtb and Mycobacterium africanum and the animal pathogens M. bovis, 
Mycobacterium microti, and Mycobacterium canettii [4] [43]. Bacteria in the MTBC are 
essentially clonal with little evidence of horizontal gene transfer with the exception of 
Mycobacterium canettii [4] [46]. These species are best adapted to their particular host 
species with a direct link between host-specific virulence and transmission despite the few 
incidences of animal-animal or human-animal transmission [4] [47]. For example M. bovis 
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used to be a significant cause of human TB primarily in children who consumed raw milk 
but its infection rate in humans has decreased since the introduction of pasteurization [48]. 
Mycobacterium leprae  (M. leprae) is the etiological agent of leprosy (also known 
as Hansen’s disease), a chronic granulomatous disease of the peripheral nerves and mucosa 
of the upper respiratory tract that has plagued human population for thousands of years [49]. 
M. leprae’s genome has been exposed to extreme reductive evolution reducing its genome 
size to almost half of the last common mycobacterial ancestor shared with Mtb. As a result, 
M. leprae have lost more than two thousand genes and only half of its genes remained 
functional [50] [51]. 
Nontuberculous mycobacteria (NTM), also called environmental mycobacteria or 
atypical mycobacteria, include all other mycobacterial species that do not belong to the 
MTBC or M. leprae group [52]. These species do not cause TB or leprosy. Members of this 
group include Mycobacterium smegmatis (Msme), Mycobacterium fortuitum (Mfort), 
Mycobacterium kansasii (Mkan), Mycobacterium marinum, and Mycobacterium avium (M. 
avium) in addition to many other species [53]. NTM are environmental species widely 
distributed in a variety environmental reservoirs such as water, protozoans, soil, marshland, 
rivers, and estuaries [53]. Disease in humans caused by NTM is believed to be acquired 
from environmental exposures. Unlike TB and leprosy, there has been no evidence of 
animal-human or human-human transmission in immunocompetent hosts [52]. Some 
species in the NTM group such as Mkan and M. avium may cause a variety of infections 
including pulmonary disease, the prevalence of which is increasing [54]. Nontuberculous 
mycobacterial species show significant variations in their growth rate, colony morphology, 
and virulence [55]. 
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Based on the ability to cause disease in their host, mycobacteria can be organized 
into three groups: virulent pathogenic, opportunistic facultative-pathogenic, and non-
pathogenic [45]. 
 
1.2.1 Virulent pathogenic mycobacteria. 
 Pathogenic virulent mycobacteria such as Mtb and M. leprae are known to cause 
serious disease in healthy humans [45] [49]. Mtb is the primary etiological agent of 
pulmonary TB and is the most virulent member of the MTBC. Mtb is a rod-shaped, aerobic, 
Gram-positive bacillus. Like other mycobacteria species, it has a very thick cell wall that 
contains a large number of mycolic acids, peptidoglycans, arabinogalactans, 
lipoarabinomannans, and phosphatidylinositol mannosides [56]. These components of the 
Mtb cell wall are shown to assist the bacillus in evading the host IR as well as resisting 
therapeutic antibacterial compounds [57] [58]. 
 
1.2.2 Opportunistic facultative-pathogenic mycobacteria. 
Other mycobacterial species are considered opportunistic facultative-pathogenic. 
These species such as M. avium, M. kansasii (Mkan), and even the vaccine strain BCG can 
cause disseminating infections in humans that are defective in the adaptive IR, but unlike 
Mtb, do not cause disease in healthy individuals [59]. M. avium and Mkan are often to be 
found as opportunistic pathogens in immunosuppressed individuals due to AIDS [59]. The 
cell wall of these bacteria contains some modifications to its lipids and mycolic acids that 
are different from Mtb [60]. 
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Mkan is a biosafety level (BSL) -2 organism and was first isolated from human 
pulmonary secretions [61]. It is considered the most virulent among environmental NTM 
and the second most common nontuberculous mycobacteria isolated from clinical 
specimens after M. avium [62] [63] . It can cause pulmonary disease in immunocompetent 
patients with preexisting pulmonary conditions like asthma and chronic obstructive 
pulmonary disease as well as disseminating extrapulmonary infections in 
immunocompromised humans with various immunodeficiencies and chronic illnesses such 
as AIDS patients [59] [64]. Mkan causes symptoms that are similar to those of Mtb 
infections, however, like other NTM, it does not transmit to other hosts and is sensitive to 
antibiotics [63]. 
 
1.2.3 Non-pathogenic mycobacteria. 
 Mycobacterial species such as Msme and Mfort are considered non-pathogenic 
since they do not cause disseminating infections even in immunocompromised and 
immunosuppressed individuals [59]. However, Msme and Mfort have been implicated to be 
causative agents of community-acquired and health care-associated diseases [59]. 
Msme was first isolated from genital secretions (smegma) of a patient with syphilis in 1885, 
hence the name ‘smegmatis’ [65] [66]. It was considered to be an environmental 
saprophyte of no clinical significance until a case of lung disease in a patient with 
underlying lipoid pneumonia caused by Msme was reported in 1986 [59] [67]. It is known 
to be a cause of localized non-disseminating infections of community-acquired disease 
involving cellulitis, localized abscesses, and osteomyelitis of wound sites following a 
traumatic event [68]. Msme has also been implicated in health care-associated diseases 
	   11	  
including sporadic cases of infected pacemaker site, catheter sepsis, sternal wound 
infection following cardiac surgery, and infections following plastic surgery [59] [67] [69]. 
Msme and Mfort contain modifications to their cell lipids and mycolic acids that are 
implied in their severe attenuation [70] [71]. These bacilli are fast growers when compared 
to pathogenic and facultative-pathogenic mycobacteria. They double at a fast rate of 
approximately 3 hours compared to 24 hours for Mtb and BCG [66]. Despite the fact that 
mycobacterial species share the same mycobacterium ancestor, non-pathogenic 
environmental species have a larger genome size (approx. 6Mb) than pathogenic Mtb 
(approx. 4Mb) [59]. This could be attributed to Mtb undergoing genome downsizing and 
extensive lateral gene transfer to become a specialized pathogen of humans without 
retaining an environmental niche. Conversely, non-pathogenic environmental species like 
Msme have maintained a relatively large genome in order to retain their capacity to resist 
the various environmental stresses and survive in an environmental niche [72]. 
Msme can be a useful model to study certain aspects of mycobacterial molecular 
mechanisms of Mtb proteins since it grows fairly rapidly and is a BSL-2 organism even 
after transfection with genes from Mtb [73]. Msme also has a number of properties that 
potentially make it an effective vaccine platform against a variety of bacterial and viral 
diseases [74] (section 1.2.4). 
 
1.2.4 M. smegmatis, a potential vaccine platform. 
 Msme has several properties that may make it an effective vaccine vector. Many 
Msme strains do not cause any disseminating disease and are commensal in humans [73] 
[75]. The bacillus is also rapidly killed by lysosomal proteases in the phagolysosome of 
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infected cells unlike other mycobacterial species such as the vaccine strain BCG, which 
survives in infected cells for months by inhibiting the fusion of the phagosome with 
lysosomal vesicles [76-80]. Furthermore, Msme induces cytokine production by host 
macrophages better than pathogenic mycobacteria [71] [81-83] [84] and can activate and 
induce the maturation of dendritic cells (DC) more efficiently than BCG by upregulating 
major histocompatibility complex (MHC) class I and costimulatory molecules [85]. Msme 
is shown to be more efficient than BCG in accessing the MHC-I pathway for presentation 
of mycobacterial antigens [86]. These immunogenic properties of Msme may make it a 
potentially good vaccine platform that is needed for the elicitation of cell-mediated 
immunity. Several groups highlighted the prominent potential of recombinant Msme 
expressing protective antigens of different pathogens and molecules that modulate the IR as 
a vaccine vector and/or immunotherapy against viral infections such as HIV [74] [87] and 
Hepatitis B [88], cancer treatment [85] [89], and bacterial infections such as Mtb [90-92] 
and Helicobacter pylori infections [93]. 
 
1.3 Immune response and mycobacteria. 
 The exposure to foreign bodies and microbial infections induces an immune 
response (IR) in the host. The IR is divided into two categories, the innate IR and the 
adaptive IR (also called acquired IR). The innate IR is the first defensive response that 
manifests in the host upon encountering the microbe. It is fast, non-specific, localized to the 
site of infection, and does not confer any chronic protection [94] [95]. In contrast, the 
adaptive IR is delayed and requires the mounting of an initial innate IR [96] [97]. It is 
specific and targeted toward the type of infectious microbe. The adaptive IR manifests in 
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two types, cellular or humoral [98]. Virulent pathogens like Mtb have the capacity to 
manipulate the host IR in order to survive and cause disease while less pathogenic bacteria 
like Msme are less potent in such manipulation [99]. In the following section we review the 
fundamentals of the IR in mammals as well as the interaction of mycobacterial species with 
the immune system. 
 
1.3.1 The immune system. 
1.3.1.1. Cytokines. 
 Cytokines play a major role in the regulation of the IR. They are cell-signaling 
protein molecules secreted by a variety of immune cells in order to regulate the IR, recruit 
other immune cells (property of chemokines), and shift the IR in either a humoral or a cell-
mediated direction [97] [100] [101]. Proinflammatory cytokines such as the tumor necrosis 
factor (TNF) [102], interferon- γ (IFN-γ) [103], IL-1β [104], IL-18 [104], and IL-12, the 
latter being proinflammatory during the primary IR [105], are all important in the IR 
against mycobacterial infections . IL-12 is secreted by macrophages upon infection and 
leads to the stimulation of T cells and the release of IFN- γ during the primary IR [105]. 
IFN- γ in turn activates macrophages making them more efficient in killing pathogens 
[106]. TNF is secreted by infected macrophages and stimulated T cells and can further 
activate macrophages, which may secrete IL-12 to further stimulate the T cells [105] [107]. 
IL-1β and IL-18 are secreted by macrophages, DCs, and neutrophils via a pathway that 
involves activation of the inflammasome (section 1.5) and lead to the induction of IFN-γ 
secretion, angiogenesis, and neutrophil influx to remove cellular debris [108]. All of these 
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cytokines are required for an efficient IR against Mtb infections since mice deficient in any 
of them are highly susceptible to Mtb infections [102] [106] [109]. 
 
1.3.1.2 Pattern recognition receptors (PRR). 
 Pattern recognition receptors (PRR) are cell surface or cytosolic receptors that 
specifically recognize pathogen associated molecular patterns (PAMP), which are secreted 
by or expressed on the surface of microbial pathogens and not by mammalian cells [110]. 
PRRs are classified into two categories: cell surface PRRs and cytosolic PRRs. 
 
Cell surface PRRs. 
The mammalian family of toll like receptors (TLR) is comprised of PRRs expressed 
on the cell surface. TLRs are vital to the initiation of the innate IR leading to activation of 
the adaptive immunity [111]. TLR signaling upon sensing of microbial PAMPs on the cell 
surface leads to the activation of transcription factors such as nuclear factor -κB (NF-κB), 
which are required for the expression of genes important for the IR [112]. Mtb cell wall 
components such as the mannose-capped lipoarabinomannans (Man-LAM) are shown to 
bind TLR-2 of DCs, which is shown to play important role in the IR against Mtb [113-115]. 
 
Cytosolic PRRs. 
Other types of PRRs are localized to the cytoplasm. Unlike TLR, these receptors 
consist of soluble proteins that survey the cytoplasm for signs that indicate the presence of 
intracellular invaders. These include the nucleotide-binding domain leucine rich repeat 
(NLR) family of proteins, the PYHIN family proteins such as absent in melanoma-2 
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protein (AIM2), and the Rig-like helicases (RLH) [110]. Cytosolic PRRs can sense 
microbial components in the cytoplasm and lead to the assembly and activation of the 
inflammasome. Inflammasome activation then leads to the activation of proteases such as 
caspase-1, which can cleave pro-IL-1β and pro-IL-18 into their mature secreted form [108] 
(section 1.5). IL-1β and IL-18 induced secretion upon inflammasome activation are shown 
to play an important role in the IR against mycobacterial infections [116-123] 
 
1.3.1.3 Cell types involved in innate immunity. 
 The innate IR is not specific to a particular pathogen. It depends on a group of 
proteins and immune cells that recognize conserved features of pathogens and become 
quickly activated to help destroy invaders [124]. The main cell types involved in the innate 
IR are the natural killer cells, eosinophils, basophils, and the phagocytic cells including 
monocytes, mast cells, macrophages, DCs, and neutrophils [124]. Here I will briefly 
discuss the two most important ones, which are most relevant for the purpose of our study: 
macrophages and dendritic cells. 
 
Macrophages. 
 Macrophages are “professional” phagocytes. They are the result of the 
differentiation of monocytes in tissues. Monocytes originate in the bone marrow from a 
common myeloid progenitor, circulate in the blood, then migrate from the circulation into 
tissues throughout the body to differentiate into macrophages or DCs [125] [126]. Through 
their phagocytic capacity, macrophages remove cellular debris, dead tissue, dying cells 
(necrotic or apoptotic), as well as foreign bodies such as microbial pathogens [127]. They 
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express a multitude of cell-surface receptors such as the scavenger receptors and TLRs. 
They also express intracellular receptors such as the NLRs. These receptors can detect 
signals from foreign bodies and microbes as well as signals that are not normally found in 
healthy mammalian cells [126] [127]. Macrophages are divided into subpopulations based 
on their anatomical location and functional phenotype, which include tissue homeostasis 
and wound healing, host defense against pathogens, and immunoregulatory functions. 
These subpopulations include bone-resident macrophages (osteoclasts), alveolar 
macrophages in the lungs, histiocytes in connective tissue, Kupffer cells in the liver, and 
microglial cells in the central nervous system in addition to many others in different tissues 
[125]. Based on their functions as proinflammatory and microbicidal or immune 
suppressers and tissue repairers, macrophages are divided into two subsets: classically 
activated macrophages (M1) and alternatively activated macrophages (M2). M2 
macrophages include all other macrophages that are not classically activated including 
‘regulatory’ macrophages, tumor associated macrophages (TAM), and myeloid-derived 
suppressor cells (MCSC) [126] [128]. M2 macrophages exhibit immune suppressive 
activity while M1 macrophages exhibit proinflammatory and microbicidal activity [128] 
[129] [129]. Here we will briefly review the M1 and M2 macrophages. M1 macrophages 
are of great importance to our discussion since they are one of the main types of phagocytic 
cells that are involved in the IR against mycobacterial infections [128]. 
 
Classically activated macrophages (M1). 
 Tissue-resident resting macrophages can engulf pathogens and foreign bodies via 
phagocytosis leading to their sequestration inside vacuoles called phagosomes. The 
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phagosome then matures, acidifies, and fuses with lysosomal vesicles to form the 
phagolysosome. The degradative enzymes contained in lysosomal vesicles, now in the 
phagolysosome, result in the breakdown of the phagosomal contents and the killing of 
sequestered microbes [130]. At this point macrophages are called ‘naïve’ since they have 
not been activated yet. Naïve macrophages become classically activated by exposure to two 
signals. Signal 1 consists of the ligation of IFN-γ (secreted by other activated macrophages 
and T cells) to surface receptors, which primes naïve macrophages for activations. The 
second signal (signal 2) is exogenous TNF binding to TNF receptor (TNFR) or an inducer 
of TNF such as TLR signaling via the ligation of PAMPS to TLR, which induces 
endogenous TNF production by the macrophage itself [131]. The macrophage then 
upregulates its antimicrobial capacity and produces nitric oxide (NO) and reactive oxygen 
species (ROS) [130]. NO and ROS are antimicrobial agents important for the killing of 
pathogens [132]. 
M1 Macrophages are also potent antigen presenting cells (APC). Once activated, 
they can upregulate the expression of major histocompatibility complex (MHC) class II 
molecules, which can present bacterial antigens on the cell surface for recognition by and 
activation of T cells [133]. Macrophages are the primary host cell for mycobacteria, 
especially alveolar macrophages, which are the main bacterial host in pulmonary TB [134].  
 
Alternatively activated macrophages (M2). 
Naïve resident tissue macrophages have the ability to respond to external stimuli 
very rapidly leading to drastic alterations in their gene expression. This rapid response 
leads to the activation of different types of macrophages [135] . The activation of naïve 
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macrophages can take a different path and result in alternatively activated macrophages 
(M2) that have regulatory and anti-inflammatory functions, which are different from the 
functions of classically activated macrophages. These M2 macrophages fail to produce NO 
and are compromised in their ability to limit the growth of intracellular pathogens [136]. 
They are also not efficient APCs and can inhibit T Cell proliferation. They secrete anti-
inflammatory interleukin (IL)-10 and IL-1 receptor antagonist [131]. M2 macrophages are 
formed in the presence of IL-4 and/or IL-13, which are secreted primarily by T helper type-
2 (Th2) cells [137], distinct from IFN-γ-mediated classical activation. M2 macrophages 
have been implicated in a range of physiological and pathological processes including 
tissue homeostasis, wound repair, regulation of inflammation, angiogenesis, metabolic 
functions, and tumorigenesis. They also play an important role in immunity against 
parasitic infections [136], allergic responses, and hypersensitivity [138]. 
 
Dendritic cells (DC) and antigen presentation. 
 Dendritic cells represent a heterogeneous cell population and reside in peripheral 
tissues especially at sites of interaction with the environment like the skin, mucosae, and 
lymphoid organs. They are phagocytic cells and the main APCs of the immune system. 
Hematopoietic stem cells in the bone marrow give rise to DC precursors that enter the 
circulation then reside in tissues as immature phagocytic cells [139].  
DCs capture exogenous antigens by phagocytosis, macropinocytosis, or via interaction with 
a variety of cell surface receptors (mostly C-type lectin family members) and endocytosis. 
DCs also process endogenous antigens from intracellular bacteria, viruses, or host’s cell 
own proteins. Antigens get processed and presented on MHC class -I or -II molecules on 
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the surface of DCs. The cells then migrate to lymphoid tissue where they present antigens 
loaded on MHC molecules to CD4+, CD8+ or memory T cells; thereby initiating immune 
responses [140]. Two types of antigen presentation pathways exist, notably MHC-I and 
MHC-II antigen presentation.  
MHC-I antigen presentation involves the presentation of endogenous cytoplasmic 
antigens derived from intracellular bacteria, viruses, or the host cell’s own proteins. 
Antigens in the cytosol are digested by an enzyme complex called the proteasome, then are 
transported to the endoplasmic reticulum (ER) where they get mounted on MHC-I 
molecules and exported to the cell surface though the Golgi apparatus for presentation to 
naïve CD8+ T cells in order to activate them and generate effector cytotoxic T lymphocytes 
(CTL) [141] [142]. The MHC-I antigen presentation enables the immune system to detect 
infected or transformed cells displaying proteins from pathogens or modified-self, 
respectively, on their surface MHC-I molecules [143]. 
MHC-II antigen presentation involves the presentation of exogenous antigens 
contained in phagosomes or endosomes following phagocytosis or endocytosis of bacteria, 
parasites, and toxins. These antigens are processed in the endosome via the activity of 
lysosome-associated enzymes, then get loaded on MHC-II molecules and trafficked to the 
cell surface for presentation to CD4+ T-helper cells [142].  
Exogenous antigens contained in endocytic compartments can also be loaded on 
MHC-I molecules for presentation to CD8+ T cells via a process called cross-presentation. 
Exogenous antigens, which are classically processed in the phagosome or endosome and 
loaded on MHC-II molecules, are instead loaded on MHC-I molecules during cross-
presentation. This cross-presentation is reported to occur via two different pathways:  
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‘cytosolic’ and ‘vacuolar’ pathways. The ‘cytosolic’ pathway involves the processing of 
exogenous antigens by the proteasome and transport of peptides to the ER where they get 
loaded on MHC-I molecules, which then get transported to the cell surface. By contrast, the 
‘vacuolar’ pathway is suggested to involve the processing and loading of antigens on 
MHC-I molecules in endocytic compartments [143].   
Mycobacterial antigens in apoptotic bodies, which result from the apoptotic death 
of infected cells can be taken up by APCs such as DCs and get cross-presented by MHC-I 
molecules to CD8+ T cells. This cross-presentation by DCs to CD8+ T cells, which leads to 
the activation and differentiation of CD8+ T cells into cytotoxic lymphocytes, is important 
during Mtb infections since DCs were shown to be necessary for the activation of 
tuberculosis-specific T cells [144], and are also shown to be bacterial hosts [145]. 
 
1.3.1.4 Cell types involved in adaptive immunity. 
 Mammalian cells involved in the adaptive IR include tow types of lymphocytes, 
notably B cells and T cells. Unlike phagocytic cells of the innate IR, B cells and T cells 
specifically recognize and mount a targeted IR against antigens [146]. 
 
B cells  
B cells are lymphocytes that can recognize antigens via interaction with their B cell 
receptors and differentiate into specialized plasma cells. Plasma cells produce antibodies 
that can recognize specific antigens and lead to their neutralization. This type of adaptive 
IR is called humoral IR [146]. We will not discus B cells in detail since they are not 
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relevant for the purpose of this discussion as the host IR against mycobacteria do not 
involve B cells and humoral immunity. 
 
T cells 
 T cells are important for another type of adaptive IR called cell-mediated response. 
They express specific receptors called T cell receptors (TCR) on their cell surface, which 
specifically bind to antigens presented on MHC molecules of APCs leading to a localized 
IR [147]. T cells exist in two distinct classes: helper T cells (CD4+) and cytotoxic T cells 
(CD8+).  
CD4+ helper T cells do not possess any cytotoxic or phagocytic capabilities. 
However, they secrete cytokines (IL-2, IL4, and IFN-γ), which activate leukocytes to kill 
pathogens. Once stimulated, CD4+ T cells differentiate into either Th1 or Th2 helper T 
cells depending on the cytokine environment [148]. Th1 helper T cells secrete IFN-γ, 
which activates macrophages and stimulate B cells to secrete specific antibodies required 
for the opsonization and neutralization of antigens via an inflammatory cell-mediated 
immunity (Th1 response). Th2 helper T cells secrete IL-4, which stimulates B cells to 
secrete antibodies used in the neutralization of antigens via anti-inflammatory humoral 
immunity (Th2 response) [148]. CD4+ T cells are important during Mtb infections. TNF 
and IL-12 secreted by Mtb-infected macrophages lead to the stimulation of CD4+ T cells to 
secrete IFN-γ, which activates macrophages rendering them more efficient in killing the 
bacilli [149]. 
 CD8+ T cells, also called cytotoxic T cells, possess TCRs that recognize antigens 
presented on MHC-I molecules on the surface of APCs. This specific recognition leads to 
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their activation and the release of cytotoxins (perforin, granzymes, and granulysin), which 
form pores in the plasma membrane of infected cells. Cytotoxins can then penetrate 
infected cells and lead to their killing via apoptosis. CD8+ T cells also secrete IFN-γ, which 
activates macrophages [150] [151].  
Both types of T cells (CD4+ and CD8+) are important for the IR against Mtb since 
mice deficient in either cell type are more susceptible to Mtb infections [152] [153]. 
 
1.3.2 Manipulation of the immune response by Mtb. 
 Mtb, though evolution, has developed many mechanisms to evade the host IR and 
persist inside its macrophage host. These mechanisms include inhibition of the fusion of 
the phagosome with the lysosome, resistance to ROS and reactive nitrogen intermediates 
(RNI), inhibition of host cell apoptosis, and formation of granulomas. 
  
1.3.2.1 Inhibition of phagolysosome fusion. 
 Mtb is known to actively inhibit the fusion of the phagosome-containing bacilli with 
lysosomal vacuoles [154]. Such fusion, if allowed, delivers lysosomal degradative enzymes 
to the phagosome leading to the killing of the bacillus. This inhibition is suggested to 
involve Mtb cell wall component Man-LAM [152] [153] and trehalose dimycolate [155], 
which along with other proteins [156] [157] inhibit the phosphoinositide 3 (PI3) kinases 
preventing the accumulation of PI3P necessary for the recruitment of early endosome 
antigen 1 (EEA1). This inhibition prevents SNARE from interacting with EEA1 leading to 
a defect in endosomal trafficking and inability of the lysosome to fuse with the phagosome 
[157]. This inhibition leads to hindered antigen processing and less presentation of Mtb-
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antigens on MHC-II, and/or MHC-I molecules via cross presentation [158] since 
mycobacterial antigens remain enclosed in phagosomes and are not released outside the 
phagosome. The formation of Mtb-containing apoptotic bodies released in the extracellular 
environment following apoptosis of infected cells is shown to compensate for this 
impediment by presenting mycobacterial antigens to neighboring bystander APCs [144]. 
 
1.3.2.2 Resistance to ROS and RNI. 
 Virulent Mtb has the capacity to neutralize the ROS produced by the host cell 
NADPH oxidase (NOX) -2 complex in the phagosome. This neutralization of ROS is 
accomplished via the secretion of bacterial superoxide dismutase (SOD) A and C [159] 
[160], and catalase G (KatG)  in the phagosome. These bacterial enzymes are shown to be 
important for the virulence of Mtb as deletion or silencing of any of them results in 
attenuated mycobacteria [29] [161]. Mtb also possesses anti-apoptotic genes such as nuoG, 
which inhibits the accumulation of ROS in the phagosome, prevents the increase of TNF 
secretion, and inhibits host cell apoptosis [162] [163]. 
Furthermore, Mtb is also shown to be able to resist the effects of iNOS-dependent RNIs, 
which are toxic to the bacteria. The activation of macrophages with IFN-γ results in the 
induction of iNOS and the production of bactericidal NO [164]. Nevertheless, Mtb 
expresses a four-proteins NADH-dependent peroxynitrate reductase complex that enables it 
to defend itself against RNIs. The deletion of one these proteins, dlaT, resulted in an 
attenuated Mtb with diminished growth in vitro and high susceptibility to killing by RNIs 
[165]. In addition, the proteasome of Mtb was shown to be required for the resistance to 
RNI since deficiency in proteasomal adenosine triphosphate resulted in the attenuation of 
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Mtb in vivo and exposure of Mtb to proteasomal protease inhibitor rendered the bacillus 
more susceptible to RNI [166] [167]. Other mycobacterial proteins have also been 
implicated in the resistance of Mtb to RNIs including MsrA and MsrB. Mtb deficient in 
both proteins is shown to be more susceptible to RNIs [168]. 
 
1.3.2.3 Inhibition of host cell apoptosis. 
Apoptosis plays an important role in the innate and adaptive IR against intracellular 
pathogens [169]. The apoptotic but not necrotic response of macrophages infected with 
intracellular mycobacteria could lead to the killing of the bacteria via different mechanisms. 
Intracellular mycobacteria could be directly killed when their host macrophage undergoes 
apoptosis [170]. Furthermore, apoptotic vesicles containing mycobacteria can be 
phagocytosed by stimulated uninfected bystander macrophages, which can then kill the 
bacteria more efficiently. These bystander macrophages get stimulated via cell surface 
receptor signaling induced by the binding of TNF and IFN-γ [171]. In addition, 
mycobacterial antigens in apoptotic bodies can be taken up by APCs such as macrophages 
and DCs and get cross-presented by MHC-I and CD1b molecules to CD8+ T cells which 
leads to the activation and differentiation of CD8+ T cells into tuberculosis-specific 
cytotoxic lymphocytes [171]. Mtb has the capacity to inhibit host cell apoptosis as one of 
the mechanism employed by the bacillus to resist the host IR and be able to hide and persist 
within macrophages and DCs [169]. This inhibition of apoptosis by Mtb was shown to 
involve several mechanisms. First, Mtb can down-regulate the expression of Fas ligand 
(FasL) expression leading to diminished Fas-mediated apoptosis of host cells [172] (section 
1.4.1.3) . Mtb is also reported to induce the production of soluble TNF receptor (TNFR)-2, 
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which then competes with TNFR-1 for TNF binding and signaling [173]. TNFR-1 
signaling is important for the induction of apoptosis in the extrinsic apoptosis pathway 
[174] (section 1.4.1.3). Furthermore, virulent Mtb can also up-regulate the expression of 
host anti-apoptotic genes of the Bcl-2 family such as mcl-1 and bfl-1 in infected cells [175]. 
Mtb also possesses anti-apoptotic genes such as nuoG, which inhibits the accumulation of 
ROS in the phagosome, prevents the increase of TNF secretion, and inhibits host cell 
apoptosis [163]. Other Mtb anti-apoptotic genes include secA2, which encodes a protein 




1.3.3 Non-pathogenic and facultative pathogenic mycobacteria and the immune response. 
Non-pathogenic mycobacteria such as Msme and Mfort are strongly attenuated and 
do not cause disseminating infections even in immunosuppressed individuals [59]. 
Facultative-pathogenic mycobacteria such as Mkan and BCG were shown to be less 
attenuated than non-pathogenic mycobacteria but less virulent than Mtb. They cause 
disseminating infections in humans that are defective in the adaptive IR, but unlike Mtb, do 
not cause disease in healthy individuals [59].  
The capacity of infected macrophages to undergo apoptosis following infection is 
an efficient mechanism of the innate IR [169]. Host cell susceptibility or resistance to 
mycobacterial infections was suggested to be linked to the capacity of the infected 
macrophages to undergo necrosis or apoptosis, respectively [177]. 
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Mycobacteria from the facultative-pathogenic and non-pathogenic groups were shown to 
induce higher levels of apoptosis in infected macrophages than virulent Mtb. Facultative-
pathogenic mycobacterial species Mkan and BCG induce more apoptosis than virulent Mtb 
in infected primary human alveolar macrophages [178]. Non-pathogenic mycobacterial 
species Msme induces significantly higher levels of apoptosis in infected human 
macrophage-like cell line THP-1 cells [162] and J774 macrophages [163] than virulent Mtb. 
The host-cell cytokine response during mycobacterial infections is regulated by 
mitogen-activated protein kinase (MAPK) pathways [179]. The facultative-pathogenic M. 
avium induced a profoundly different host cell signaling response when compared to the 
non-pathogenic Msme [82]. In particular, the infection with Msme led to an increased p38 
and ERK1/2 MAPKs activity in mouse bone marrow derived macrophages (BMDM), 
which was necessary for increased TNF secretion [82]. In addition, sphingosine kinase, 
phosphoinositide-specific phospholipase C, and conventional protein kinase C were all 
implicated in Msme-induced activation of Erk1/2 [180]. One downstream target of the 
MAPK p38 was determined to be the transcription factor cyclic AMP response element 
binding protein (CREB), which was more activated in Msme-infected cells than M.avium-
infected cells [181].  
The characterization of the strong IR mounted by the host against facultative-
pathogenic and non-pathogenic mycobacteria compared to the diminished IR against 
virulent mycobacteria (Mtb) is of great importance for the understanding and unveiling of 
mechanisms employed by virulent Mtb to manipulate the host IR in order to persist and 
cause disease. This comparative analysis is one of the main subjects of our study. 
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1.4 Programmed cell death. 
 Programmed cell death (PCD) is the death of cells in any form, provided that it is 
mediated by intracellular pathways [182]. PCD pathways include apoptosis, programmed 
necrosis, pyroptosis, pyronecrosis, and autophagy. 
 
1.4.1 Apoptosis. 
 Apoptosis is a form of PCD employed by multicellular organisms for tissue 
development, selection of lymphocytes during development of the immune system, general 
homeostasis, and host defense against invading pathogens. During apoptosis, biochemical 
events lead to characteristic morphological cell changes and subsequent death. These 
changes include cell shrinkage and blebbing, nuclear fragmentation, chromatin 
condensation, fragmentation of chromosomal DNA, and the formation of an impermeable 
cellular envelope [183]. Following these events, the cell eventually disintegrates into 
vesicles called apoptotic bodies. Apoptotic bodies are then taken up by neighboring 
phagocytes such as macrophages, DCs, and neutrophils. In this fashion mycobacteria-
infected cells that undergo apoptosis are able to sequester mycobacterial antigens in 
apoptotic bodies, which get ingested by neighboring APCs and get presented on MHC-I 
molecules leading to the activation of cell-mediated IR [171] [184].  
 Apoptosis is mediated by proteases called caspases, which can be activated via 
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1.4.1.1 Caspases. 
Caspases are highly conserved cysteine-aspartic proteases responsible for the 
cleavage of a multitude of cellular substrates as part of the apoptosis pathway. Genes 
encoding caspases are expressed to yield an immature uncleaved form of the protein called 
pro-caspase. Inactive pro-caspases are cleaved by other proteases in order to become active 
[182]. Two types of caspases are involved in the apoptosis process: initiator caspases 
(caspases 2,8,9,10,) and effector caspases (caspases 3,6,7) [186] [187]. A third type 
includes inflammatory caspases (caspases 1,4,5 in humans and caspases 1,11,12 in mice) 
[188]. Initiator caspases are the first proteases to be activated in response to apoptotic 
stimuli. Many pro-caspases contains a caspase recruitment domain (CARD) and death 
effector domain (DED). CARD is required for the interaction between caspases while DED 
is required for the interaction of pro-casapses with the formed activation complex (DISC or 
apoptosome) in response to an apoptosis-inducing signal. Activated initiator caspases 
cleave effector pro-caspases to yield active effector caspases. The active effector caspases 
then cleave a cascade of intracellular proteins to carry out the cell death program [187] 
[189]. 
 
1.4.1.2 Intrinsic apoptosis pathway. 
 The intrinsic apoptosis pathway is activated in response to internal stress 
experienced by the cell such as extensive DNA damage, radiation exposure, or loss of 
survival factors [174] [187]. This pathway involves the mitochondria, which affected by 
internal stress, gets depolarized and its outer membrane gets permeabilized. This process is 
called mitochondrial outer membrane permeabilization (MOMP) [190]. In this pathway the 
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pro-apoptotic Bcl-2 family member proteins such as Bax, Bak, and Bok translocate to the 
mitochondria upon stimulation causing the release of cytochrome C from the mitochondria. 
Cytochrome C then binds to the apoptotic protease activating factor-1 (Apaf-1). Apaf-1 
contains a CARD domain and can form the oligomeric apoptosome complex, which 
includes cytochrome c, Apaf-1, and procaspase-9. The apoptosome complex then activates 
the initiator caspase pro-caspase-9. This leads to cleavage and activation of caspase-9 and 
the initiation of a cascade leading to activation of caspase-3 and induction of apoptosis 
[174] [187] [190] (Figure2). 
 
1.4.1.3 Extrinsic apoptosis pathway. 
The extrinsic apoptosis pathway involves external signals and the binding of ligands 
such as Fas ligand (FasL) and TNF to cell surface receptors. FasL binds to Fas on the cell 
surface and leads to the activation and direct binding of Fas cytoplasmic death domain to 
Fas-associated death domain (FADD) [174]. In the case of TNF signaling, TNF binds to 
TNFR-1 on the cell surface via interaction of their death domains. Subsequently a TNFR-1 
associated death domain (TRADD) binds to TNFR-1 and recruits FADD protein. In both 
pathways FADD recruits and binds to the initiator pro-caspase-8 to form a complex called 
DISC (death-inducing signaling complex). Pro-caspase-8 gets activated within the complex 
DISC then gets released to further activate effector caspase-3. The activation of caspase-3 
is where both intrinsic and extrinsic apoptosis pathways converge and continue a cascade 
of events leading to cell death [174] [187] (Figure 2). 
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1.4.1.4 TNF signaling: dual role in apoptosis and survival. 
 In addition to being an inducer of apoptotic cell death, TNF is also important for the 
induction of proinflammatory response and cell survival. TNF binding to TNFR-1 may lead 
to recruitment and binding to the proteins RIP1, TRADD, TRAF2, and cIAP1 and 
activation of either Jun/Fos or NF-κB, followed by gene transcription, and production of 
inflammatory mediators and survival proteins. On the other hand, TNF binding to the death 
receptor TNFR-1 may also initiate Jun N-terminal kinase (JNK) activation, which can 
inhibit TNF-induced apoptosis and lead to activation of caspase-8 and downstream effector 
caspases such as caspase-3 resulting in apoptosis [191] (Figure 3). It is important to note 
that intracellular levels of ROS can activate MAP kinases leading to JNK activation. 
Sustained JNK activation can shift the TNF signaling pathway toward host cell apoptosis 
instead of NF-κB driven cell survival pathway [191]. This is significant since mycobacteria 
can inhibit the influx of ROS into the phagosome via the action of NuoG, which diminishes 
JNK activation and apoptosis [163].  
 
1.4.2 Caspase-independent apoptosis. 
 Caspase-independent apoptosis is defined as a cell death pathway that leads to DNA 
fragmentation and does not depend on caspases for initiation and activation. It is often 
mediated by proteolytic enzymes released from the mitochondria that are not dependent on 
caspases for activation. For example, Apoptosis inducing factor (AIF) [192-194] and 
endonuclease G [195], are enzymes released from the mitochondria and are involved in 
initiating a caspase-independent pathway of apoptosis leading to chromatin condensation 
and DNA fragmentation. Lysosomal enzymes like cathepsins are sometimes released from  














Adapted from [174]. 
 
Figure 2. Extrinsic and intrinsic pathways of apoptosis. (A) The extrinsic apoptosis pathway. Upon 
Fas ligation (CD95 in the figure) FADD and procaspases-8 and -9 are recruited to the cytoplasmic side 
of the receptor forming the DISC complex. Caspases-8 and -10 become activated and go on to cleave 
and activate the effector caspases. (B) The intrinsic apoptosis pathway. In the presence of a death signal 
or the absence of pro-life signals, levels of the pro-apoptotic Bcl-2 family proteins (Bax, Bad, Bim) can 
overcome the number of anti-apoptotic proteins (Bcl-2, Bcl-xL) and induce MOMP. This mitochondrial 
permeabilization allows for the release of the pro-apoptotic proteins cytochrome C and SMAC/Diablo. 
Cytochrome C binds to APAF1 to create the apoptosome, which can bind to and activate the initiator 
caspase-9, which in turn activates the effector caspases-3, -6, and -7 to induce apoptosis. SMAC/Diablo 
can bind to inhibitor of apoptosis proteins that can inhibit caspase activation. Although these two 






















Adapted from [191]. 
 
Figure 3. TNF signaling via TNFR-1 leading to both cells death (apoptosis) and 
survival. Binding of TNF to TNFR-1 leads to recruitment of RIP1, TRADD, TRAF2, and 
cIAP1to form complex I. Complex I transduces signals leading to NF-κB translocation. At 
later time points, RIP1, TRADD, and TRAF2 dissociate from TNFR-1 and recruit FADD 
and caspase-8 to form complex II. In the absence of NF-κB activity from complex I, 
complex II can initiate caspase-8 activation and cell death. NF-κB inhibits cell death 
through upregulation of antiapoptotic genes such as c-FLIP, which directly inhibits caspase 
activation in complex II or through suppression of JNK activity, possibly through 
upregulation of A20. Sustained TNFR-1-mediated JNK activation results in the cleavage of 
Bid to jBid, which then induces the preferential release of SMAC from the mitochondria. 
Released SMAC interferes with cIAP1-mediated inhibition of caspase-8. 
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‘leaky’ lysosomes and can induce apoptosis via a caspase-independent pathway [196-198]. 
Mtb has been shown to induce the lysosomal CIA pathway when infecting host cells at high 
multiplicity of infection (MOI) [199].  
 
1.4.3 Autophagy. 
 Autophagy is a catabolic process that involves the degradation of the cell’s own 
components through lysosomal degradation often in response to stress and/or starvation. It 
involves the sequestration of large cytoplasmic components and organelles in autophagic 
vacuoles and the subsequent digestion of the vacuoles contents by lysozymes upon fusion 
of the autophagic vacuoles with lysosomic vesicles [200] [201]. Macro autophagy, which 
involves the sequestration and digestion of most of the cytoplasm leads to cell death in a 
caspase-independent manner [202]. Autophagy also plays a role in the host defense against 
mycobacterial infections since Mtb-infected cells that undergo autophagy are shown to be 
able to reduce the viability of the bacilli [203] [204]. This is probably possible since 
autophagic vacuoles can sequester and digest Mtb-containing phagosomes leading to the 
killing of the bacteria. This process would overcome the need of the phagosome to fuse 
with the lysosome.  
 
1.4.4 Necrosis. 
 In contrast to apoptosis, necrosis is sometimes considered to be passive and 
therefore un-programmed form of cell death. It is the premature death of cells induced by 
external factors such as infection, inflammation, toxins, trauma from injury, and oxygen 
deprivation [205]. Necrosis is independent of caspases and usually begins with cell 
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swelling, chromatin digestion, and disruption of the plasma and organelle membranes. At 
the nuclear level, necrosis is distinguished from apoptosis by the persistence of the DNA 
content, which remains uncondensed [206].The integrity of the plasma membrane is 
another key difference between apoptosis and necrosis since necrosis results in the 
disruption of the plasma membrane and the expulsion of cytosolic content when the cell 
bursts while apoptosis maintains the integrity of the membrane [205]. This feature is 
important in the context of immune and inflammatory response since the necrotic cell death 
results in is the expulsion of cellular components into the local environment. Some of these 
components can become proinflammatory. In addition, necrotic macrophages can release 
proinflammatory cytokines such as TNF and IL-12 [206]. 
 
1.4.5 Pyroptosis. 
 Pyroptosis is a newly identified PCD pathway that somehow resembles both 
apoptosis and necrosis. It is activated by microbial pathogens during inflammation 
including Listeria and Salmonella species. It is similar to apoptosis in that it is dependent 
on caspases and results in DNA damage. However, unlike apoptosis, it does not depend on 
classical apoptotic caspases (casapse-3, -8, and -9) but is rather dependent on casapse-1 
[206]. Pyroptosis is similar to necrosis in that the plasma membrane breaks down. Recent 
studies implicated the involvement of the apoptosome, which is described as a large 
complex comprised of ASC (apoptosis-associated speck-like protein containing a caspase-
recruitment domain (CARD)) dimers. This is important from an inflammation standpoint 
since ASC is an adaptor molecule that interacts with NOD-like receptors (NRL) and is 
required for the activation of most inflammasomes (section 1.5). This is in addition to the 
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Pyronecrosis is another newly identified proinflammatory PCD pathway that 
depends on NRL, ASC, and Cathepsin B for activation. It resembles necrosis in that it does 
not depend on caspases, results in membrane degradation, does induce chromatin 
condensation, and does not involve DNA fragmentation [206]. 
 
1.5 Inflammasomes and mycobacteria. 
 Pathogens, upon invasion of the host, are first faced by the innate IR carried on by 
phagocytic cells such as macrophages, monocytes, and neutrophils [207]. The activation of 
macrophages and neutrophils, which leads to the release of bactericidal ROS and RNI, is 
dependent on proinflammatory cytokines such as IL-1β and IL-18. These proinflammatory 
cytokines are secreted primarily from infected macrophages and monocytes. The inactive 
precursors of IL-1β and IL-18 (pro- IL-1β and pro-1L-18, respectively) require processing 
and cleavage by caspase-1 to become active. Casapse-1 is an inflammatory caspase that 
gets activated within a multimeric protein platform called the inflammasome [207]. In the 
following we review the components of inflammasomes, the mechanisms of inflammasome 
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1.5.1 The inflammasome. 
1.5.1.1. Inflammasome components. 
 The Inflammasome is a multimeric protein complex that classically (with some 
exceptions) contain a member of the nucleotide and oligomerization domain (NOD)-like 
receptor (NLR) family, the adapter molecule apoptosis-associated speck-like protein 
containing a CARD (ASC), and caspase-1 [208]. NLRs are cytosolic PRRs that, similar to 
cell surface TLRs, detect a variety of conserved microbial components and danger signals 
induced by microbes within intracellular compartments. These microbial components and 
danger signals are called pathogen associated molecular patterns (PAMP) and danger 
associated molecular patterns (DAMP), respectively. Examples of PAMPs and DAMPs 
sensed by NLRs are microbial cell wall components, microbial DNA, bacterial RNA, 
flagella, muramyl dipepetide (MDP), uric acid crystals, and β-amyloid [208] [209]. 
Another identified inflammasome called AIM2 contains a PYHIN protein family member 
called absent in melanoma-2 (AIM2) instead of an NLR [208]. NLRs share a domain 
organization that is usually comprised of an amino-terminal protein-protein interaction 
domain such as the caspase recruitment domain (CARD) or pyrin domain, a NACHT 
domain that is required for nucleotide binding and self oligomerization, and a number of 
carboxy-terminal leucine-rich repeat (LRR) motifs involved in sensing PAMPs and 
DAMPs [108] [210].  
 
1.5.1.2 Inflammasome activation and IL-1β / IL-18 processing. 
ASC adapter protein plays an important role in the interaction between NLRs or 
AIM2 with caspase-1 [208]. Upon detection of cellular stress via the sensing of PAMPs 
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and/or DAMPs, NLR molecules oligomerize through homotypic interactions between 
NACHT domains leading to the exposure of their pyrin domain (PYD), which can then 
interact with PYD of ASC. As a result, CARD of ASC interacts with CARD of inactive 
pro-caspase-1 leading to auto-activation of caspase-1. Active caspase-1 can then cleave 
proinflammatory cytokines precursors pro- IL-1β and pro-IL-18 into their mature active 
form (IL-1β and IL-18) [108]. 
 The activation of IL-1β and IL-18 is a two-step process that requires two signals. 
Signal 1 involves the pattern recognition of microbes by host cells, which induces the 
expression and transcription of pro-IL-1β and pro-IL-18. The second signal (signal 2) 
involves the activation of the inflammasome by DAMPs and/or PAMPs, which results in 
the activation of caspase-1 and the cleavage of pro-IL-1β and pro-IL-18 to yield their 
mature active form [207].  
 
1.5.1.3. Types of inflammasomes. 
 To date, several types of inflammasomes have been identified. However, only few 
are well characterized. They vary in the type of activating PAMPs or DAMPs from 
different microorganisms as well in some of their components. The most studied 
inflammasomes include NLRP1, NLRP3, IPAF (also know as NLRC4), NLRC5, NOD-1, 
NOD-2, and AIM2 inflammasomes [108] [208] [211].  
  
NLRP3 inflammasome. 
 The NLRP3 inflammasome, also called cryopyrin or NALP3, is the most well-
characterized inflammasome. It is expressed in myeloid cells and is up-regulated in 
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response to the stimulation of macrophages and DCs to PAMPs [212]. It consists of the 
cytosolic PRR NOD-like receptor-3 (NLRP3) proteins, which upon sensing of microbial 
components or danger signals gets oligomerized and exposes its PYD domain. The exposed 
PYD domain then interacts with PYD of ASC leading the activation of caspase-1 via 
CARD-CARD domains interaction. NLRP3 does not posses a CARD domain so it requires 
ASC to activate caspase-1, which only contain a CARD domain but no PYD domain [108]. 
The activation of caspase-1 via NLRP3 inflammasome activation leads to the activation 
and secretion of IL-1β and IL-18 [108] (Figure 4).  
The NLRP3 inflammasome has been shown to play an important role in the 
inflammatory response induced by several activators such as low intracellular potassium 
concentrations, influenza A, Neisseria ghonorrhoeae, bacterial toxins, cholesterol crystals, 
monosodium urate (MSU), and mycobacterial infections [108], the latter being of great 
importance for the purpose of our analysis. NLRP3 inflammasome has also been implicated 
in metabolic disorders (obesity and type-2 diabetes) [213], cancer [214], intestinal 
inflammation [215], and liver injury [216]. In the addition to its proinflammatory role in 
innate immunity, the NLRP3 inflammasome has also been suggested to play an important 
role in shaping the adaptive IR via the secretion of IL-1β and IL-18 [108].  
Several models have been described for the activation of the NLRP3 
inflammasome: the channel mode, the lysosome rupture model, and the ROS model [108]. 
• The channel model involves the release of ATP at the site of cellular injury or 
necrosis leading to the activation of the P2X7 ATP-gated ion channel, which results in a 
rapid efflux of potassium ions from the cell. This efflux of K+ ions leads to the recruitment 
of pore-forming pannexin-1 hemichannels, which then allow extracellular NLRP3 
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activators such as bacterial products to access the cytoplasm and activate NLRP3. This 
activation model only allows small activators to cross the plasma membrane into the 
cytoplasm but not large molecules [108].  
• The lysosome rupture model involves inefficient clearance of activating particles 
via lysosomal digestion following phagocytosis, leading to the release of cathepsin B into 
the cytoplasm and activation of NLRP3 receptor molecules. This model of activation is 
efficient for large activator molecules as they are internalized via phagocytosis [108].  
The ROS model is dependent on the generation of ROS. ROS generation is frequently 
accompanied by K+ efflux and it is possible that low intracellular K+ concentrations trigger 
ROS production and vice versa. Treatment with NLRP3 agonists leads to the association of 
NLRP3 with thioredoxin-interacting protein (TXNIP, also know as VDUP1) in a ROS-
dependent manner. TXNIP is constitutively bounds and inhibited by oxireductase 
theoredoxin. An increase in ROS concentration leads to the dissociation of the TXNIP-
theoredoxin complex, which results in release of unbound TXNIP and subsequent binding 
to NLRP3 molecules and activation of the inflammasome [108].  
 
AIM2 inflammasome. 
 The AIM2 inflammasome is activated upon sensing of double stranded DNA 
(dsDNA) in the cytoplasm, as oberserved with Francisella infections [217]. Unlike other 
NLR inflammasomes, which use an NLR family protein as a PRR, the AIM2 
inflammasome uses a PYHIN family protein member called absent in melanoma-2 (AIM2) 
as the PRR for the sensing of microbial dsDNA. AIM2 is localized to the cytoplasm and it 
 
















Adapted from [108]. 
 
Figure 4. Mechanism of NLRP3 inflammasome complex formation. Under healthy cellular conditions, 
NLR family, pyrin domain-containing 3 (NLRP3) is auto-repressed owing to an internal interaction 
between the NACHT domain and LRRs. This auto-repression is removed in the presence of 
pathogenassociated molecular patterns (PAMPs) from microorganisms or damage-associated molecular 
patterns (DAMPs) from endogenous danger signals. This results in exposure of the NACHT domain. In 
turn, NLRP3 oligomerizes and recruits apoptosis-associated speck-like protein containing a CARD (ASC; 
also known as PYCARD) and pro-caspase-1, triggering the activation of caspase-1 and the maturation and 
secretion of proinflammatory cytokines such as interleukin-1β (IL-1β) and IL-18. Other cytoplasmic 
proteins, such as enzymes of the glycolytic pathway, are also substrates of active caspase-1. CARD, 
caspase-recruitment domain; LRRs, leucine-rich repeats; NACHT, NAIP, CIITA, HET-E and TP1; PYD, 
pyrin domain. 
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contains a PYD domain that engages ASC via PYD-PYD interaction leading to the 
activation of caspase-1 and subsequent maturation of pro-IL-1β and pro-IL-18. A recent 
report suggested that AIM2 plays an important role in Mtb infections since mice deficient 
in Aim2 were more susceptible to Mtb infection than wild type (WT) mice [108] [212].  
  
Other inflammasome types. 
  Other inflammasomes such as NLRP1, IPAF (also called NLRC4), have been 
described while others such as NLRP6, NLRP10, and NLRP12 are identified but not well 
characterized. IPAF requires ASC for the activation of caspase-1 since it contains a PYD 
domain but no CARD. NLRP1 unlike other NLRs contains both PYD and CARD domains 
and has the ability to either activate casapse-1 directly and/or via ASC [208] [212].  
 
1.5.2 Mycobacteria-induced inflammasome activation and the role of IL-1β in 
mycobacterial infections. 
 IL-1β and IL-18 are shown to play an important role in the host defense against Mtb 
as was reported in vivo in studies where mice deficient in IL-1 receptor (IL-1R), IL-1β or 
IL-18 were more susceptible to Mtb infections [116] [117] [122] [218] [219]. 
Inflammasome activation leads to secretion of IL-1β and IL-18, which are important for the 
host defense against Mtb infections. Mtb-infected BMDMs and THP-1 cells induced IL-1β 
secretion, which was dependent on ASC, NLRP3, and caspase-1 [220] indicating an 
important role for NLRP3 inflammasome in the immune response against Mtb. However, 
in vivo infections of mice deficient in Asc and caspase-1 did not display any decrease in IL-
1β secretion compared to WT mice, and these knockout mice were less susceptible to Mtb 
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infections than Il-1β knockout mice. Furthermore, a recent study showing that mice 
deficient in Aim2 were more susceptible to Mtb infections than WT mice suggests an 
important role of AIM2 in the immune response against Mtb infections [221].  
The discrepancy between in vivo and in vitro Mtb-induced secretion of IL-1β 
suggests that cell types other than macrophages are involved in the processing and 
secretion of IL-1β. These cell types might also involve mechanisms other than 
inflammasome activation leading to the secretion of IL-1β. Our analysis of mycobacteria-
infected DCs, which are also an important host for mycobacteria besides macrophages 
[145] [230-232], addresses these questions. 
 
1.6 Specific aims and significance. 
 Mtb infects approximately two billion people worldwide, making it a major global 
health problem. The only available vaccine BCG was shown to be unreliable since it does 
not confer consistent protection in humans. Furthermore, the drug chemotherapies used 
against TB are becoming ineffective due the emergence of drug-resistant Mtb in addition to 
them being inconvenient due to the rather long 6-9 months treatment. It is therefore evident 
that the development of a new vaccine as well as new antibiotics capable of clearing TB 
infections are needed to keep fighting this disease and prevent it from spreading beyond 
control. Mtb has evolved to acquire mechanisms that allow it to manipulate the host IR, and 
hide and persist within the host. The pathogen inhibits host cell apoptosis, prevents the 
fusion of phagosome with lysosome, and resists ROS and RNI. In comparison, less 
pathogenic mycobacteria of the facultative-pathogenic group such as Mkan and BCG as 
well as non-pathogenic mycobacteria such as Msme and Mfort, do not possess such 
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capacities to resist the host IR. Non-pathogenic Msme and Mfort have been shown to be 
strongly attenuated and do not cause disseminating infections even in 
immunocompromised individuals. These mycobacterial species induce a very strong host 
innate IR, potent cytokine production by host macrophages, and can activate and induce the 
maturation of DCs for presentation of antigens on MHC molecules better than pathogenic 
and opportunistic mycobacteria such as Mtb and BCG, respectively. Msme has also been 
shown to be a potentially good vaccine platform for several diseases like tuberculosis, 
cancer, AIDS, Hepatitis B, gastritis, and gastric ulcers. It is therefore important to exploit 
and further analyze the immunogenic properties of non-pathogenic mycobacteria as a 
strategy to study and better understand the mechanisms of the host innate IR. The 
comparison of non-pathogenic to more pathogenic mycobacterial species can also be used 
as a strategy to understand how pathogenic mycobacteria developed mechanisms to evade 
the host IR and cause disease. These analyses will also provide us with better strategies for 
the use of non-pathogenic mycobacteria as a recombinant vaccine vector for various 
microbial infections, viral infections, and diseases.  
The focus of our research was the analysis of the mechanisms of the IR induced by 
non-pathogenic mycobacteria in macrophages and DCs, two main cell types involved in 
innate immunity and the induction of the adaptive IR. Therefore, we first aimed to analyze 
the mechanisms by which non-pathogenic mycobacteria strongly induce apoptosis, an 
important innate immune mechanism, in macrophages and dendritic cells. Then we amimed 
to analyze the molecular mechanisms of Msme-induced IL-1β secretion in DCs and 
macrophages. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Materials. 
 WT BALB/c and C57BL/6 mice were obtained from the National Cancer Institute. 
Casp1-/-, Nlrp3-/-, Asc-/-, and Il1r1-/- mice have been described elsewhere {Adachi, 1998 
#118;Mariathasan, 2004 #119;Sutterwala, 2006 #120}. Aim2-/- mice were obtained from Dr. 
Fitzgerald (University of Massachusetts Medical School). Caspase-specific inhibitors, 
cathepsin and calpain inhibitors, and their analogs were purchased from Calbiochem 
(www.emdbiosciences.com). Neutralizing anti-mouse TNF antibody was purchased from 
Peprotech Inc (www.peprotech.com). Anti-mouse IFN-β antibody was purchased from 
abcam (www.abcam.com). Anti-mouse dectin-1 antibody was purchased from InvivoGen 
(www.invivogen.com). All other reagents were purchases from Sigma (www.sigma.com) 
unless otherwise noted. 
 
2.2 Bacteria and culture conditions. 
M. smegmatis strain (mc2 155) was obtained from Dr. William Jacobs Jr. M. 
fortuitum strain (ATCC 6841) and M. kansasii strain Hauduroy (ATCC 12478) were 
obtained from the American Type Culture Collection (http://wwwatcc.org). M. bovis BCG 
Pasteur strain was obtained from the Trudeau Culture Collection (Saranac Lake, New York, 
United States). M. tuberculosis H37Rv (ATCC 25618) and M. tuberculosis H37Ra (ATCC 
25177) were obtained from Dr. W.R. Jacobs Jr. (Albert Einstein College of Medicine). F. 
tularensis Live Vaccine Strain (LVS) (ATCC 29684) was obtained from Dr. Kevin McIver 
(University of Maryland, College Park). GFP-expressing BCG and M. smegmatis were 
generated by subcloning the enhanced GFP gene (Clonetech, http://www.clonetech.com) 
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into the mycobacterial episomal expression vector pMV261. The resulting plasmid 
(pYU921) was transfected into competent cells by electroporation as previously described. 
M. smegmatis, M. fortuitum, M. kansasii, and M. bovis BCG were cultured in 7H9 broth 
with 0.5% glycerol, 0.5% dextrose, and 0.05% TWEEN-80. For selective media, 40 µg/ml 
kanamycin was added. F. tularensis LVS was cultured in MH broth supplemented with 
0.015% anhydrous CaCl2, 0.02% hydrous MgCl2, 0.1% dextrose, 0.025% ferric 
pyrophospate, and 2% Isovitalex supplement (Invitrogen, USA). 
 
2.3 Cell culture conditions and infection. 
For the apoptosis and IL-1β secretion assays, 5 x 105 BMDMs and BMDCs in 
DMEM supplemented with 10% fetal calf serum, and 2% HEPES (infection media) were 
seeded on each well of a 24 well plates. Bacteria were grown to an OD600 ranging from 0.2 
to 0.8, passed through a 26 Gauge needle three times and allowed to settle for 10 minutes. 
The infection was carried out at a multiplicity of infection (MOI) of 1:1, 3:1, and 10:1 for 
the apoptosis assays and MOI of 10:1 for the IL-1β secretion assay. Infections were carried 
out for two hours in duplicate wells, after which extracellular bacteria were removed by 
three washes using 1x phosphate buffered saline (PBS). The cells were then incubated in 
DMEM infection medium supplemented with 100 µg/ml gentamicin (Invitrogen) for 20 
hours and the apoptosis assay was performed.  
 
2.4 Bone-marrow derived macrophages and dendritic cells. 
BALB/c and C57Bl/6 mice were maintained under pathogen-free conditions and 
used between 6 to 12 weeks of age and sacrificed by CO2 asphyxiation or isoflurane 
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inhalation followed by cervical dislocation in accordance with IACUC approved protocols. 
The anterior limbs were flushed with DMEM supplemented with 2% fetal calf serum. 
Flushed bone marrow cells were then pelleted and treated with 1x red blood cells lysis 
buffer (eBiosciences) for 10 minutes then washed with 1x PBS. For macrophage 
differentiation, cells were then plated on Petri dishes in DMEM supplemented with 10% 
heat inactivated fetal calf serum, 15% L cell-conditioned medium (LCCM), 1% 
Penicillin/Streptomycin, then incubated at 37°C / 5% CO2. Cells were supplemented with 
additional medium on days 3 and 6. On day 7, all non-adherent cells were washed off and 
the remaining adherent bone marrow derived macrophages were seeded on appropriate 
plates for infection. To derive dendritic cells, cells were incubated in medium as described 
for macrophages but containing 20 ng/ml murine GM-CSF (Peprotech) instead of LCCM. 5 
x 106 cells/plate were added to Petri dishes containing 10 ml medium and an additional 9 
ml medium/well were added on days three and six. On day 8, all non-adherent dendritic 
cells were collected and seeded on appropriate plates for infection. 
 
2.5 Apoptosis assays. 
In most of the experiments the flow cytometry-based hypodiploid assay was used 
for the detection of apoptosis after infection of BMDMs and BMDCs. Cells were collected 
after infection, pelleted and resuspended in propidium iodine (PI)/RNase buffer (BD 
Pharmingen) for 20 minutes and the percentage of hypodiploid-positive cells was 
determined by flow cytometry in duplicates in the FL-2 channel at 580 nm (FACS-Calibur, 
BD Biosciences). The TUNEL assay was performed to reveal apoptosis-induced DNA 
fragmentation in tissue culture cells using the In Situ Cell Death Kit, Fluorescein (Roche 
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Applied Science). The assay was carried out as described by the manufacturer and as 
described previously [162] and the percentage of stained cells was analyzed using flow 
cytometry. 
 
2.6 Enzyme-linked immunosorbent assays (ELISA). 
For the TNF, IL-12, IL-1β, and pro- IL-1β secretion assays, 5 x 105 BMDMs or 
BMDCs in DMEM infection media were seeded onto each well of 24 well plates (500 
µl/well) and infected with bacteria as previously indicated. The culture supernatants were 
then collected 20 hours after incubation in infection media supplemented with 100 µg/ml 
gentamicin. The amount of TNF, IL-12, IL-1β, and pro- IL-1β in supernatants were then 
measured via ELISA (BD Bioscience for TNF and IL-12 detection, and eBioscience for IL-
1β and pro- IL-1β detection).  
 
2.7 ROS detection assays. 
Reactive oxygen species (ROS) in BMDMs and BMDCs were detected at 2 hours 
post-infection using the ROS sensitive dye dihydroethidium (DHE) (Invitrogen). BMDMs 
or BMDCs were deprived of LCCM or rGM-CSF respectively 16 hours prior to infection 
and maintained in cytokine free media without phenol red for the length of the experiment. 
Post-infection, cells were washed once in HBSS and then incubated in 2 µM DHE for 15 
minutes. Cells were washed three times with HBSS, fixed with 4% paraformaldehyde and 
analyzed by flow cytometry. 
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2.8 Enzymes inhibition and protein neutralization assays. 
BMDMs and BMDCs from BALB/c and/or C57Bl/6 mice were treated with a pan 
caspase -inhibitor (100 µM), caspase-3 inhibitor negative control (100 µM), caspase-1 
inhibitor (100 µM), caspase-8 inhibitor (100 µM), caspase-9 inhibitor (100 µM), cathepsin 
B/S/L inhibitor (100 µM), and calpain inhibitor (100 µM) (all from Calbiochem), anti-
murine TNF neutralizing antibody (5 µg/ml), isotype control antibody (5 µg/ml) (both from 
BD Bioscience), anti-IFN-β neutralizing antibody (5 µg/ml) (Abcam), anti-dectin-1 
neutralizing antibody (5 µg/ml) (InvivoGen), or pentoxifylline (Sigma, 100 µg/ml) for one 
hour at 37°C / 5% CO2 and infected with M. smegmatis at MOI 10:1 for two hours as 
previously described. Cells were then washed three times in 1x PBS and incubated for an 
additional 20 h in DMEM infection media supplemented with the appropriate inhibitors 
and controls and the apoptosis assay was performed. 
 
2.9 Determination of infection rate and bacterial load. 
For the rate of infection assay, BALB/c and C57Bl/6 BMDMs and BMDCs were 
infected with GFP-expressing Msme and BCG for two hours at MOIs 3:1 and 10:1. At this 
point cells were washed and the number of infected cells was determined by flow 
cytometry (GFP fluorescence intensity shifts) (0 hours post-infection time point). A second 
set of cells were washed with 1x PBS and incubated for an additional 20 hours in infection 
medium supplemented with 100 µg/ml gentamicin as previously described and the number 
of infected cells was determined by flow cytometry (GFP fluorescence intensity shifts) (20 
hours post-infection time point). 
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For the bacterial load assay, BALB/c and C57Bl/6 BMDMs and BMDCs were 
infected with GFP-expressing Msme and BCG for 2 hours at MOIs 3:1 and 10:1. At this 
point cells were washed and the numbers of colony forming units (CFU) in infected cells 
were quantified on agar plates (0 hours post-infection time point). A second set of cells 
were washed with 1x PBS and incubated for an additional 20 hours in infection medium 
supplemented with 100 µg/ml gentamicin as previously described and the numbers of 
CFUs in infected cells were quantified on agar plates (20 hours post-infection time point) 
 
2.10 Statistical analysis. 
Statistical analysis was performed on at least three independent experiments using 
GraphPad Prism 5.0 software and One-way ANOVA with Tukey post-test unless otherwise 
noted in the figure legends. Shown are representative results of triplicate values with 
standard deviation. The range of p-values is indicated as follows: ns = not significant, * = 
0.01< p <0.05,   ** = 0.001< p <0.01, and *** = 0.0001< p <0.001. 
 
 
CHAPTER 3. RESULTS AND DISCUSSION 
3.1 Mechanisms of non-pathogenic mycobacterial species M. smegmatis and M. 
fortuitum induced apoptosis in macrophages. 
Non-pathogenic mycobacteria such as Msme and Mfort were shown to be strongly 
attenuated [59]. Facultative pathogenic mycobacteria such as Mkan and BCG were shown 
to be less attenuated than non-pathogenic mycobacteria but also less virulent than Mtb [59]. 
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The following studies address the mechanisms by which non-pathogenic mycobacterial 
species (Msme and Mfort) induce a rapid host cell innate IR. 
 
3.1.1 Non-pathogenic mycobacteria induce increased host cell apoptosis in macrophages 
compared to facultative-pathogenic mycobacteria. 
 In order to test the apoptotic response of macrophages when infected with non-
pathogenic compared to facultative-pathogenic mycobacteria, we used bone marrow 
derived macrophages (BMDM) from BALB/c mice and infected them with Msme, Mfort, 
Mkan, or BCG for duration of 2 hours. The cells were then washed and incubated in 
infection medium supplemented with gentamicin for an additional 20 hours. The 
percentage of apoptotic cells was determined by quantifying the fraction of cells in 
hypodiploid state via flow cytometry (Figure 5). 75-80% of BMDMs infected with Msme 
and Mfort were hypodiploid positive, which was significantly different from BMDMs 
infected with facultative-pathogenic Mkan and BCG (p <0.001) (Figure 5). Concurrently, 
BMDMs infected with BCG and Mkan did not show any significant increase in the levels 
of apoptosis compared to the untreated control (UT) cells during the entire course of this 
short-term 22 hours infection (p >0.05) (Figure 5).  
This observed difference in apoptotic induction is also conserved in human macrophage-
like cells (THP-1 cell line). THP-1 cells are a good model for the study of the behavior of 
primary human alveolar macrophages in response to mycobacterial infections [222]. PMA 
(Phorbol myristate acetate)-differentiated THP-1 cells were infected with Msme, Mfort, 
Mkan, or BCG for 2 hours then washed and incubated in infection medium supplemented 
 





















Figure 5. Differences in apoptosis induced by facultative-pathogenic versus non-
pathogenic mycobacteria in primary murine macrophages. Differentiated BALB/c 
BMDMs were infected at an MOI of 10:1 with M. smegmatis (Msme), M. fortuitum (Mfort), 
M. kansasii (Mkan), M. bovis BCG or left untreated (UT). The percentage of apoptotic cells 
was determined using a propidium iodide (PI) based staining protocol to detect the 
population of hypodiploid cells via flow cytometry at 20 hours after infection. 
Representative histograms are shown in A. B. The average and standard deviation of three 
independent experiments is shown. For this and all subsequent figures asterisks indicate 
statistical significance with ns = p >0.05, * = 0.05>p > 0.01, ** = 0.01>p > 0.001 and *** 
= p < 0.001 which was determined using one way ANOVA using GraphPad Prism 5.0 
software. 
 


















Figure 6. Difference in apoptosis induction between facultative-pathogenic and non-
pathogenic mycobacteria in a human macrophage cell line. PMA-differentiated THP-
1 cells were at an MOI of 10:1 with M. smegmatis (Msme), M. fortuitum (Mfort), M. 
kansasii (Mkan), M. bovis BCG or left uninfected (UI) and the amount of apoptosis was 
determined 20 hours after infection using TUNEL assay and flow cytometry on duplicate 
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with gentamicin for an additional 20 hours. The percentage of apoptotic cells was 
determined by TUNEL assay. Msme-infected cells showed a 4-fold increase in apoptosis 
(approx. 40% of total cells) and Mfort-infected cells showed a 6-fold increase in apoptosis 
(approx. 60% of total cells) (Figure 6) when compared to cells infected with facultative-
pathogenic Mkan and BCG where approximately 10% of infected cells underwent 
apoptosis (Figure 6). 
These results indicate that non-pathogenic mycobacteria strongly induce higher 
levels of apoptosis when compared to facultative-pathogenic mycobacteria. This difference 
in the apoptotic response supports the hypothesis that non-pathogenic mycobacteria induce 
a very potent innate IR when compared to facultative-pathogenic mycobacteria. 
 
3.1.2 Non-pathogenic mycobacteria strongly induce the secretion of TNF and IL-12 in 
macrophages. 
 TNF is a central proinflammatory cytokine that mediates and regulates innate 
immunity. TNF binding to TNFR-1 may lead to activation of either Jun/Fos or NF-KB, 
followed by gene transcription, and production of inflammatory mediators and survival 
proteins. On the other hand, TNF binding to the death receptor TNFR1 may also initiate 
JNK protein kinase activation followed by activation of caspase-8 and downstream effector 
caspases such as caspase-3 resulting in apoptosis of the cell [223]. 
In order to examine the effect of TNF on the induction of apoptosis by non-
pathogenic mycobacteria, BALB/c BMDMs were infected with Msme, Mfort, Mkan, or 
BCG at three different MOIs (1:1, 3:1, and 10:1) for 2 hours. The cells were then washed 
and incubated in infection medium supplemented with gentamicin for an additional 20 






























Figure 7. Differences in TNF secretion and Il-12 p40 induction between facultative-
pathogenic and non-pathogenic mycobacteria-infected macrophages. A. BALB/c 
BMDMs were infected at MOIs of 1:1, 3:1, and 10:1 with M. smegmatis (Msme), M. 
fortuitum (Mfort), M. kansasii (Mkan), M. bovis BCG, or left untreated (UT). Cells were 
infected in triplicates for two hours then washed and incubated in infection media with 100 
µg/ml gentamycin for an additional 20 hours. Culture supernatants were then collected and 
the amount of secreted TNF was determined using ELISA. The values are the mean and 
standard deviation of triplicate readings and they are representative of three independent 
experiments. B. The induction of Il-12 p40 gene expression was analyzed by infecting 
RAW/pIL-12-GFP macrophages with the indicated bacteria for two hours at an MOI of 
10:1. The GFP-expression was analyzed on 5,000 cells 16 hours later and the mean and 
standard deviation of three independent experiments are shown. 
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hours. The amounts of secreted TNF in the supernatant were measured via ELISA. 
BMDMs infected with Msme secreted 10 to 18 times more TNF than BMDMs infected 
with facultative-pathogenic Mkan or BCG, which did not secrete any significant amounts 
of TNF (Figure 7A). Concurrently, BMDMs infected with Mfort also secreted 
approximately 10-fold more TNF than macrophages infected with BCG or Mkan (Figure 
7A). In a similar fashion, non-pathogenic mycobacteria had a much stronger impact on the 
expression of Il-12 gene in RAW/pIL-12 GFP reporter cell line infected with Msme and 
Mfort at MOI 10:1 compared to cells infected with BCG or Mkan at similar MOI (Figure 
7B). Msme and Mort infections resulted in p40 promoter-driven GFP expression in 
approximately 30% of infected cells, whereas infection with BCG or Mkan resulted in GFP 
expression of merely 5-10% of infected cells (Figure 7B). 
These results demonstrate a stronger induction of two proinflammatory cytokines 
(TNF and IL-12) in macrophages when infected with non-pathogenic mycobacterial 
species (Msme and Mfort) compared to facultative-pathogenic mycobacteria (BCG and 
Mkan). 
 
3.1.3 Non-pathogenic mycobacteria induce apoptosis via TNF and caspase-3 signaling 
pathways. 
 We showed that non-pathogenic mycobacteria induce a strong apoptotic response 
and TNF secretion in BALB/c macrophages (Figures 5B and 7A) when compared to 
facultative-pathogenic mycobacteria. Apoptosis of eukaryotic cells could follow either a 
caspase-dependent or caspase-independent pathway. All caspase-dependent pathways lead 
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to the activations of effector caspases-3, -6, and 7 [224]. Caspase-independent pathways 
involve lysozymes and do not lead to the activation of caspases. 
In order to determine which pathway is involved in the macrophage apoptotic response to 
non-pathogenic mycobacteria infection, we pretreated BALB/c BMDMs with caspase-3 
inhibitor, TNF neutralizing antibody, Pentoxifylline (PTX, chemical inhibitor of TNF 
synthesis), the appropriate controls, or left the cells untreated then infected them with 
Msme at MOI 10:1 for two hours. The cells were then washed and incubated in infection 
medium supplemented with gentamicin as well as the same concentrations of inhibitors and 
antibodies for an additional 20 hours. Host cell apoptosis was determined on 10,000 cells 
using the hypodiploid flow cytometry assay. Cells treated with the caspase-3 inhibitor 
showed a significant 20-fold decrease in apoptosis (1.2% apoptotic cells) when compared 
to the untreated (UT) Msme-infected control (20% apoptotic cells) and to cells treated with 
the inactive chemical analog of the caspase-3 inhibitor (16.8%) (Figure 8). In a similar 
fashion, TNF neutralizing antibody (1.1% apoptotic cells) and Pentoxifylline (PTX) treated 
cells (5.5% apoptotic cells) both showed a significant decrease in apoptosis compared to 
UT Msme-infected cells (20% apoptotic cells) or the non-specific antibody-treated cells 
(21% apoptotic cells) (Figure 8). These results demonstrate that apoptosis of  



























Figure 8. Macrophage apoptosis induction by a nonpathogenic mycoabcteria is 
caspase-3 and TNF-dependent. BMDMs from BALB/c mice were left untreated and 
uninfected (UT) or infected with M. smegmatis at MOI 10:1 and then either left in medium 
(Msme) or treated with caspase-3 inhibitor (C3I), nonspecific chemical analog (C3I-A) 
neutralizing TNF antibody (TNF-Ab), nonspecific control Ab (Co-Ab) and TNF synthesis 
inhibitor pentoxifylline (PTX). The percentage of apoptotic cells out of 10,000 total cells 
was determined after 20 h using the hypodiploid PI flow cytometry assay and a 
representative histogram of two independent experiments performed in duplicates is shown. 
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3.1.4 Non-pathogenic mycobacteria do not induce apoptosis in C57Bl/6 BMDMs. 
 We showed that non-pathogenic mycobacteria induce a strong apoptotic response 
and TNF secretion in BALB/c macrophages compared to facultative-pathogenic 
mycobacteria. We also demonstrated that this apoptotic induction in macrophages is 
dependent upon TNF and caspase-3 activation. These results were all observed in BMDMs 
originating from BALB/c mice. In order to account for the different genotypes of the host’s 
macrophages, we also derived macrophages from C57Bl/6 mouse bone marrow and 
infected them with non-pathogenic and facultative-pathogenic mycobacteria as was done 
for BALB/c BMDMs. C57Bl/6 BMDMs infected with Msme and Mfort did not show any 
increased levels of apoptosis when compared to BCG or Mkan infected cells or untreated 
cells (UT) as the percentages of hypodiploid positive cells (Figure 9A) and TUNEL 
positive cells (Figure 9B) were similar across all conditions (p >0.05). There was no 
significant increase in apoptosis in any infected BMDMs. These results demonstrate that 
the apoptotic response upon infection with non-pathogenic mycobacteria is dependent on 
the genotype of the host.  
 Since non-pathogenic mycobacteria did not induce apoptosis in infected C57BL/6 
BMDMs in contrary to BALB/c BMDMs (compare Figures 5B to Figures 9A and 9B) it 
was important to check the levels of secreted TNF by C57BL/6 macrophages upon 
infection with non-pathogenic mycobacteria. C57BL/6 BMDMs secreted nearly 5-fold 
more TNF when infected with Msme or Mfort compared to infections with BCG or Mkan, 
the latter of which did not induce the secretion of any TNF (Figure 9C). The total amount 
of TNF secreted after Msme infection is reduced in C57BL/6 versus BALB/c BMDMs 
(compare Figures 7A and 9C). For example at an MOI of 10:1, Msme induced the secretion 






















Figure 9. Mycobacteria do not induce rapid apoptosis in BMDMs originating from 
C57Bl/6 mice. A. Differentiated C57Bl/6 BMDMs were infected at an MOI of 10:1 with M. 
smegmatis (Msme), M. fortuitum (Mfort), M. kansasii (Mkan), M. bovis BCG or left 
untreated (UT). The percentage of apoptotic cells was determined using a propidium iodide 
based staining protocol to detect the population of hypodiploid cells via flow cytometry at 
20 hours after infection. B. C57Bl/6 BMDMs were infected as in A. or incubated with the 
apoptosis inducer staurosporine (ST) and the amount of apoptosis was detected using 
TUNEL staining and flow cytometry analysis. C. Macrophages were infected at MOIs of 
1:1, 3:1, and 10:1 with M. smegmatis (Msme), M. fortuitum (Mfort), M. kansasii (Mkan), M. 
bovis BCG, or left untreated (UT). Culture supernatants of triplicate wells were collected 
after 20 hours and the amounts of secreted TNF was determined using ELISA. In A. and B. 
the data shown is the mean and standard deviation of three independent experiments. In C. 
the values are the mean and standard deviation of triplicate readings of one experiment and 
they are representative of three independent experiments. 
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of 16.7 ± 2.7 ng/ml TNF in BALB/c BMDMs (Figure 7A) but only the secretion of 4.4 ± 
0.7 ng/ml TNF in C57BL/6 BMDMs (p <0.01) (Figure 9C). This difference in TNF 
secretion between BALB/c and C57BL/6 BMDMs could be interpreted as evidence for the 
role of decreased TNF secretion in the absence of Msme-induced apoptosis. On the other 
hand, the amounts of TNF secretion induced by infection of either mouse strains with Mfort 
are similar (compare Figures 7A and 9C). For example at an MOI of 10:1, Mfort induces 
the secretion of 6.2 ± 2.0 ng/ml TNF in BALB/c BMDMs (Figure 7A) and the secretion of 
4.9 ± 1.1 ng/ml TNF in C57BL/6 BMDMs (p  > 0.01) (Figure 9C). In contrast to this 
unchanged amount of secreted TNF in C57Bl/6 BMDMs, Mfort like Msme only induces 




Apoptosis plays an important role in the innate IR against intracellular pathogens. 
The apoptotic but not necrotic response of macrophages infected with intracellular 
mycobacteria could lead to killing of the bacteria via different mechanisms. Intracellular 
mycobacteria could be directly killed when their host macrophage undergoes apoptosis 
[170]. Furthermore, apoptotic vesicles containing mycobacteria can be phagocytosed by 
stimulated uninfected bystander macrophages, which can then kill the bacteria more 
efficiently. These bystander macrophages get stimulated via cell surface receptor signaling 
induced by the binding of TNF and IFN-γ [171]. In addition, mycobacterial antigens in 
apoptotic bodies can be taken up by APCs such as macrophages and DCs and get cross-
presented by MHC-I molecules to CD8+ T cells which leads to the activation and 
differentiation of CD8+ T cells into tuberculosis-specific cytotoxic lymphocytes [171]. This 
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cross presentation by MHC-I is very important since pathogenic Mtb inhibits the fusion of 
the mycobacteria-containing phagosome with the lysosome [158] [171]. Furthermore, 
recent studies have demonstrated that virulent Mtb expresses proteins that are shown to be 
involved in the active inhibition of host cell apoptosis. These proteins include the 
superoxide dismutase A (SodA), catalase G (KatG), and NuoG that is part of the NDH-1 
protein complex[160] [163] [225]. The deletion of any of these genes in Mtb strongly 
attenuates the bacteria suggesting that host cell apoptosis inhibition is a virulence pathway. 
Facultative-pathogenic mycobacteria cause disseminating disease in individuals 
deficient in the adaptive IR. To the contrary, humans deficient in the adaptive IR do not get 
disseminating disease when infected with non-pathogenic mycobacteria such as Msme and 
Mfort. The inability of non-pathogenic mycobacteria to cause disease in individuals lacking 
adaptive immunity suggests that the innate IR in these individuals is sufficient to defend 
against these species of mycobacteria. Non-pathogenic mycobacteria are killed early in 
infection, which suggests that their attenuation might be due to their strong induction of 
apoptosis in their macrophage host. Our results showing that non-pathogenic mycobacteria 
induce increased host cell apoptosis in macrophages compared to facultative-pathogenic 
mycobacteria (Figures 5 and 6) strongly support the hypothesis that the inability of non-
pathogenic species of mycobacteria to cause disease could be due to their capacity to 
induce a strong innate IR.  
This strong induction of apoptosis in macrophages is fast as it is observed within 22 
hours post infection as shown in Figure 5. It is important to pay attention to this relatively 
fast induction of apoptosis by non-pathogenic Msme and Mfort when compared to 
facultative-pathogenic mycobacteria since the latter have been shown to induce 
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significantly more apoptosis in primary human alveolar macrophages than four different 
strains of Mtb after 5 days of infection [178]. Therefore, it is important to note that 
facultative-pathogenic mycobacteria do induce significant amounts of apoptosis in infected 
host cells but this host response only takes place late in infection (5 days post infection). 
The fast 22 hours post-infection apoptotic response is only seen in non-pathogenic 
mycobacterial infections suggesting the presence of potent mycobacterial ligands in non-
pathogenic species capable of inducing host cell signaling [162].  
The cell wall of mycobacteria contains several components with 
immunomodulatory activities. The differential modification of the mycobacterial cell wall 
lypoglycan ‘lipoarabinomannan’ (LAM) by different mycobacterial species is correlated 
with the ability of these species to induce apoptosis and IL-12 production in macrophages, 
two very important innate immunity components [70] [226]. The mannose cap 
modification on LAM of Mtb (Man-LAM) does not induce apoptosis and IL-12 production 
in macrophages and is found to be involved in the inhibition of phagosome maturation and 
IFN-γ signaling in macrophages whereas; the addition of phosphoinositide residues on 
LAM of Msme (PI-LAM) have an opposite effect since it induces a strong proinflammatory 
response in macrophages and DCs by inducing apoptosis and IL-12 production [70] [226]. 
These lipid modifications of the cell wall (PI-LAM) are shown to mediate their biological 
activity via interaction with TLR-2 [70]. We have shown in published data [71] that PI-
LAM purified from non-pathogenic Msme and Mfort induced a significant increase in 
apoptosis and IL-12 secretion when compared to Man-LAM purified from facultative-
pathogenic Mkan and BCG in THP-1 macrophages . We have also shown in this published 
study that the purified PI-LAM and Man-LAM only interact with TLR-2 surface receptors 
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but not TLR-4 [71]. These results suggest that the PI-component in non-pathogenic 
mycobacteria is the ligand of TLR-2. 
Previous studies have demonstrated increased cytokine secretion such as TNF in 
primary mouse macrophages, human peripheral blood derived macrophages, and 
neutrophils in response to non-pathogenic Msme infection compared to opportunistic 
facultative-pathogenic M. avium [81] [83] [227]. It was also shown that virulent Mtb 
induces very little secretion, if not negligible, of TNF in mouse BMDMs [162] and 
neutrophils [227]. Our results confirm these findings and add to them by extending the 
analysis to include additional non-pathogenic mycobacteria (Mfort) and additional 
facultative-pathogenic mycobacteria (BCG and Mkan). This broad analysis of 
proinflammatory cytokines secretion by macrophages infected with several non-pathogenic 
and facultative-pathogenic mycobacterial species indicate that the strong proinflammatory 
response elicited by infected macrophages might be a more general characteristic of non-
pathogenic mycobacteria. The increased TNF secretion in murine BMDMs infected with 
Msme has been shown to be dependent on increased stimulation of cAMP/protein Kinase A 
and Calcium/Calmodulin/Calmodulin Kinase pathways, which result in prolonged 
activation of MAPKs p38 and ERK1/2 [83]. Furthermore, Msme but not M. avium have 
been shown to induce an increase in Tnf and Nos2 promoter activity in RAW macrophage 
cell line, which was also dependent on Ets and NF-κB transcription factors [83] [228]. Our 
results showing that apoptosis induced by Msme and Mfort is dependent on TNF adds to 
these previous findings by linking the increase in TNF secretion to the pro-apoptotic 
capacity of non-pathogenic mycobacteria (Figure 8) and by characterizing this apoptosis 
pathway as being caspase-dependent (Figure 8). 
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The comparison of Msme-induced TNF secretion in BAlB/c versus C57Bl/6 
BMDMs revealed that secreted TNF was reduced to almost half the amount in C57Bl/6 
BMDMs compared to BALB/c BMDMs (compare Figures 7A and 9C). In parallel, 
apoptosis induced by Msme in C57Bl/6 BMDMs was absent when compared to the 
increased induction of apoptosis in BALB/c BMDMs (compare Figures 5A and 9C). These 
findings provide evidence for the role of decreased TNF secretion in the absence of 
apoptosis induced by Msme in C57Bl/6 BMDMs. However, this correlation was not 
entirely observed in Mfort infected BALB/c and C57Bl/6 BMDMs (Figures 5A and 9C). 
Our results showed similar amounts of TNF secreted by BALB/c and C57Bl/6 BMDMs 
when infected with Mfort but the induction of apoptosis was still absent in C57Bl/6 
BMDMs (Figure 9A) compared to increased induction in BALB/c BMDMs (Figure 5B). 
As a result we hypothesized that a certain amount of TNF secretion is necessary but not 
sufficient to mediate apoptosis induction in infected BMDMs. A recent study by Miller et 
al. [163] has shown a similar pattern between the induction of TNF secretion and apoptosis 
induction in host macrophages. A pro-apoptotic Mtb mutant (ΔnuoG) still induced 
increased TNF secretion but not host cell apoptosis in C57Bl/6 BMDMs lacking functional 
phagocyte NADPH oxidase (NOX2), thus incapable of generating reactive oxygen species 
(ROS) in the phagosome. It is therefore logical to speculate that BALB/c and C57Bl/6 
NOX2 enzymes react differently upon phagocytosis of non-pathogenic mycobacteria. In 
this hypothesis, the BALB/c NOX2 complex would induce a stronger and more prolonged 
activity resulting in greater release of phagosomal ROS. This increase in ROS could to a 
sustained JNK activation and shift the TNF signaling pathway toward host cell apoptosis 
instead of NF-κB driven cell survival pathway [229]. 
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3.2 Differences in apoptosis induced by facultative-pathogenic and non-pathogenic 
mycobacteria in BALB/c and C57Bl/6 dendritic cells. 
 Thus far we examined the innate IR in BMDMs from BALB/c and C57BL/6 mice 
induced by non-pathogenic and facultative-pathogenic mycobacteria. Mtb primarily infects 
and resides in alveolar macrophages of infected humans. However, alveolar macrophages 
are not the only host for Mtb. It has been shown that in the lungs of infected mice, Mtb 
resides in large percentage in DCs [145] [230-232]. DCs are also shown to be necessary for 
the activation of Mtb-specific T cells and the transport of the bacilli from the lungs to the 
local lymph nodes [144] [145]. Therefore, we sought to examine the difference in the 
apoptotic response induced by non-pathogenic and facultative-pathogenic mycobacteria in 
BALB/c and C57Bl/6 bone marrow derived dendritic cells (BMDC) and compare it to the 
response we already characterized in BMDMs. 
 
3.2.1 Msme and BCG infect BALB/c and C57Bl/6 dendritic cells at the same rate. 
 In order to account for any difference in the rate of infection of non-pathogenic 
Msme and facultative-pathogenic BCG we examined the infection rate of both species in 
BMDCs. BALB/c and C57Bl/6 BMDCs were infected with GFP-expressing Msme and 
BCG for two hours at MOI 3:1 and 10:1 then washed and incubated in media with 
gentamicin for an additional 20 hours. The number of infected cells was determined by 
flow cytometry (GFP fluorescence intensity shifts) at 0 hours and 22 hours post infection. 
The rate of infection was similar across all conditions and cells (Figure 10A). 
 Msme is a relatively fast growing bacterium (approx. three hours duplication time) 
when compared to the slow growing BCG (approx. 24 hours duplication time). In order to  
























Figure 10. Rate of infection and intracellular growth of Msme and BCG in BMDCs. A. BALB/c and 
C57Bl/6 BMDCs were infected with GFP-expressing Msme and BCG for two hours at MOI 3:1 and 10:1 
then washed and incubated in media with gentamycin for an additional 20 hours. The number of infected 
cells was determined by flow cytometry (GFP fluorescence intensity shifts) at 0 h and 20 h post infection. 
B. BALB/c and C57Bl/6 BMDCs were infected with Msme and BCG at MOI 3:1 and 10:1. The numbers 
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account for this significant difference in growth rate, we used an infection time of 2 hours, 
which is not enough for fast growing Msme to duplicate. We also examined the bacterial 
load in BALB/c and C57Bl/6 BMDCs infected with Msme and BCG at MOIs 3:1 and 10:1. 
The numbers of colony forming units (CFU) in infected cells were quantified on agar plates 
at 0 hours and 20 hours post infection. The numbers of CFUs were similar across all 
conditions and cells (p >0.05) (Figure 10B). 
 
3.2.2 Non-pathogenic mycobacteria induce increased host cell apoptosis in BALB/c and 
C57Bl/6 dendritic cells compared to facultative-pathogenic mycobacteria. 
 In order to test the apoptotic response of DCs when infected with non-pathogenic 
compared to facultative-pathogenic mycobacteria, we infected BMDCs from BALB/c and 
C57Bl/6 mice with Msme or BCG for duration of 2 hours. The cells were then washed and 
incubated in infection medium supplemented with gentamicin for an additional 20 hours. 
The percentage of apoptotic cells was determined by quantifying the fraction of cells in 
hypodiploid state via flow cytometry (Figure 11). Both BALB/c and C57Bl/6 BMDCs 
showed significantly higher levels of apoptosis induced by non-pathogenic Msme 
compared to facultative-pathogenic BCG (compare Figures 11A and 11B). Approximately 
60% of both BALB/c and C57Bl/6 BMDMs infected with Msme were hypodiploid positive 
(p < 0.0001) (Figures 5B and 9A), which was significantly higher than BALB/c BMDCs 
infected with BCG (25% hypodiploid positive cells) (Figure 11B) and BCG-infected 
C57Bl/6 BMDCs (15% hypodiploid positive cells) compared to approximately 5% 
hypodiploid positive untreated cells (Figure 11A).  
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3.2.3 Facultative-pathogenic mycobacteria induce more apoptosis in BMDC than BMDMs. 
Despite the fact that the levels of apoptosis in BCG-infected BALB/c and C57Bl/6 BMDCs 
are significantly lower than those of Msme-infected BMDCs, these levels of apoptosis 
(25% for BALB/c and 15% for C57Bl/6) are significantly higher than the levels of 
apoptosis in BMDMs (compare Figures 5B and 9A to Figure 11). These results suggest that 
BMDCs are inherently more susceptible for undergoing apoptosis upon infection with 
facultative-pathogenic mycobacteria than BMDMs in the BALB/c background. These 
results also indicate that there is a profound difference between BMDMs and BMDCs in 
C57Bl/6 mice in regard to apoptosis induction upon infection with non-pathogenic 
mycobacteria since Msme-infected C57Bl/6 BMDMs did not show any levels of apoptosis, 
whereas about 60% of Msme-infected C57Bl/6 BMDCs were apoptotic (compare Figures 
9A to 11A).   
 
3.2.4 Differences in ROS response to mycobacterial infections between C57Bl/6 
macrophages and dendritic cells. 
Previous studies have shown an increased activity of NOX2 enzyme complex in 
DCs compared to a lower level of activity in macrophages [233]. This increased NOX2 
activity induces an increase in phagosomal ROS, which is required to maintain a neutral 
PH in the phagosome to prevent the degradation of antigens required for cross presentation 
by DCs and subsequent recognition by T cells [233]. This increase in ROS level in the 
phagosome of DCs have been shown to shift the balance of TNFR-1 signaling toward cell 
death via apoptosis by activating JNK [223] [229]. In order to address the potential role of	  
 




















Figure 11. Differences in apoptosis induced by facultative-pathogenic and non-
pathogenic mycobacteria in BALB/c and C57Bl/6 dendritic cells. C57Bl/6 (A) and 
BALB/c (B) bone marrow derived dendritic cells (BMDC) were infected at an MOI of 10:1 
with M. smegmatis (Msme), M. bovis BCG or left untreated (UT). After two hours, the cells 
were washed and incubated in infection media with 100 µg/ml gentamycin for an additional 
20 hours. The percentage of hypodiploid cells of a total of 10,000 cells was determined 
using flow cytometry. The values of the means and standard deviations of three 
independent experiments are shown. 
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ROS in the apoptosis induction in C57Bl/6 macrophages and DCs, we infected C57Bl/6 
BMDMs and BMDCs with Msme or BCG for 2 hours followed by 20 hours incubation in 
infection medium supplemented with gentamicin, or incubated the cells with opsonized 
zymosan positive control for 4 or 24 hours, or left them untreated (UT). We then measured 
the amount of ROS accumulation in the cells using dihydroethidium (DHE) and quantified 
it by flow cytometry. In BMDMs, only the opsonized zymosan positive control induced an 
increase in ROS accumulation after 24 hours incubation (Figure 12A). In contrast, in 
BMDCs, Msme induced high levels of ROS accumulation when compared to untreated 
cells (UT) (Figure 12B). Furthermore, BCG also induced a significant amount of ROS 
accumulation in DCs (Figure 12B). However, this increase in ROS accumulation in BCG-
infected BMDCs was lower than the one induced in Msme-infected BMDCs (Figure 12B). 
 
3.2.5 Discussion. 
 It was important to characterize the apoptotic response in DCs upon infection with 
non-pathogenic and facultative-pathogenic mycobacteria since DCs are also a host for Mtb 
[145] [230-232]. We have shown that BMDMs and BMDCs display the same pattern of 
apoptosis induction upon infection with non-pathogenic compared to facultative-
pathogenic mycobacteria, with the former inducing much higher levels of apoptosis. 
However, in contrast to BMDMs, BCG-infected BMDCs showed a significant increase in 
apoptosis induction after one day of infection, which was not observed in BMDMs (Figures 
5B, 9A, and 11). Concurrently, The significant levels of apoptosis induction in Msme-
infected C57Bl/6 BMDCs compared to the absence of apoptosis in Msme-infected C57Bl/6 
 





















Figure 12. Differences in ROS response to mycobacterial infections between C57Bl/6 
macrophages and dendritic cells. Cells were infected as described in figure 8 and ROS 
were detected two hours after infection using dihydroethidium (DHE). A. BMDM or B. 
BMDC left untreated (UT), infected with BCG, M. smegmatis (Msme) or incubated with 
opsonized zymosan particles for 4 hours or 24 hours. The increase in DHE mediated 
fluorescence (FL-2) was analyzed by flow cytometry of 10,000 total cells. A representative 
of three independent experiments is shown. [Experiment performed in collaboration with 
Dr. Hana Abdalla]. 
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BMDMs (compare Figures 9C and 11A) indicate that there is an underlying difference 
between BMDCs and BMDMs in C57Bl/6 mice in regard to the induction of apoptosis 
upon infection with non-pathogenic mycobacteria. This difference could be attributed to an 
increase in ROS accumulation in BMDC phagosomes upon infection with Msme. Our 
results showed that the amount of ROS in C57Bl/6 BMDCs was significantly increased 
upon infection with Msme when compared to Msme-infected C57Bl/6 BMDMs (Figure 12). 
Dendritic cells play an important role in the host defense against Mtb acting as 
professional APCs. Antigen-specific T cells recognize antigens presented on MHC 
molecules on the surface of DCs. Antigens from intracellular bacteria are presented on 
MHC-I molecules on the surface of DCs via cross-presentations [233]. This presentation of 
antigens is important for the initiation of the adaptive cytotoxic IR [233] [234]. In order to 
prevent degradation of antigens in the phagosome, the phagosomal acidity should be tightly 
regulated to a neutral PH. This regulation of the PH in the phagosome is due to NOX2 
recruitment into the phagosome, which induces the production of low levels of ROS 
causing an active and maintained alkalinization of the phagosome [163]. Consequently, this 
increase in phagosomal ROS can lead to a sustained JNK activation and shift the TNF 
signaling pathway toward host cell apoptosis instead of NF-κB driven cell survival 
pathway [163]. Our results support the argument that DCs are more susceptible to 
infection-induced apoptosis due to their capacity to generate high levels of ROS due to 
sustained NOX2 activity when compared to the rapid induction and inactivation of NOX2 
in macrophages [163]. 
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3.3 Molecular mechanisms of M. smegmatis-induced IL-1β secretion in dendritic cells 
and macrophages. 
 The inflammasome was shown to play an important role in the host defense against 
Mtb as was reported in vivo in studies where mice deficient in the IL-1 receptor (Il-1r), Il-
1β, or Il-18 genes were more susceptible to Mtb infections [116] [117] [122] [218] [219]. 
Mtb infections in BMDMs and THP-1 cell line induced IL-1β secretion, which was 
dependent on ASC, NLRP3, and caspase-1 [104] [122] [218] [235-237]. However, in vivo 
infections of mice deficient in Asc and caspase-1 did not display any decrease in IL-1β 
secretion compared to wild type (WT) mice. These knockout mice were also less 
susceptible to Mtb infections than Il-1β deficient mice [116] [117] [122] [218] [219]. This 
discrepancy between in vivo and in vitro macrophages suggests that cell types other than 
macrophages are involved in the processing and secretion of IL-1β. These cell types might 
also involve mechanisms other than inflammasome activation leading to secretion of IL-1β. 
Alveolar DCs are host cells for Mtb besides macrophages in vivo highlighting their 
importance for host defense against tuberculosis [145] [230-232]. DCs were shown to be 
necessary for the activation of Mtb-specific T cells and the transport of Mtb from the lungs 
to the local lymph nodes [163]. Unlike in macrophage [121] [220] [236-239], the 
interaction between mycobacteria and host cell inflammasome has not been well analyzed 
in dendritic cells. As stated, previous studies have established the importance of IL-1β in 
the host defense against Mtb infections [240]. Therefore, it is important to characterize the 
regulation of IL-1β in host DCs upon infection with mycobacteria. The following studies 
address the regulation of IL-1β secretion in DCs upon infection with the proinflammatory 
non-pathogenic mycobacterial species Msme. We also compare the capacity of a multitude 
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of virulent, opportunistic, and non-pathogenic mycobacterial species to induce secretion of 
IL-1β in addition to the difference in the involvement of several inflammasome 
components in IL-1β secretion in DCs. 
 
3.3.1 Msme-induced IL-1β secretion in dendritic cells is dependent on ASC but partially 
independent of NLRP3 and caspases-1, and -11. 
In order to characterize the components that are involved in inflammasome 
activation and IL-1β secretion induced by Msme in DCs, we used BMDCs from C57Bl/6 
WT mice and mice deficient in Nlrp3 (Nlrp3-/-), Asc (Asc-/-), or Caspase-1/11 (Casp1/11-/-) 
and infected them with Msme for duration of two hours at MOI 10:1 or left them uninfected. 
The cells were then washed and incubated in infection medium supplemented with 
gentamicin for an additional 20 hours. The amounts of secreted IL-1β in the supernatants 
were measured via ELISA. Casapse-1 and Caspase-11 genes are tightly adjacent to each 
other in the mouse genome and separated by only 1,500 base pairs, therefore, backcrossing 
over multiple generations yielded a caspase-1 knockout that is also lacking casapse-11. As 
a result the casapse-1 knockout strains is in fact a Caspase-1/11-/- double knockout [241]. 
WT BMDCs infected with Msme secreted large amounts of IL-1β (approx. 13 ± 0.6 ng/ml) 
while Asc-/- BMDCs did not secrete any significant amounts of IL-1β upon infection with 
Msme compared to the uninfected control (Figure 13A). This indicated that Msme-induced 
IL-1β secretion in BMDCs requires ASC. Furthermore, Casp1/11-/- and Nlrp3-/- BMDCs 
showed a significant decrease in IL-1β secretion upon infection with Msme (Figure 13A), 
which indicates that caspase-1/11, and NLRP3 are important for the secretion of IL-1β. 
However, this decrease in IL-1β was only partial and the amount of secreted cytokine was  



















Figure 13. Msme-induced IL-1β secretion is dependent on ASC but partially 
independent of NLRP3 and caspases-1/11. BMDCs were derived from WT, caspase-1/11-
/-, ASC-/-, NLRP3-/-, and IPAF-/- mice and infected with Msme or left uninfected (UI). The 
supernatants were harvested after 22 hours and the amount of secreted IL-1β (A) and pro- 
IL-1β (D) were detected by ELISA. The amounts of AK in the supernatant were measured 
via Toxilight AK release colorimetric assay (C). The positive control (Pos Ctrl) indicates 
complete cell lysis via treatment with Triton-X (B). Shown are the percentages of 
hypodiploid positive cells. Shown are means and standard deviation of triplicate 
measurements of one representative experiment out of three. 
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still significant (approx. 7.5 ng/ml for Nlrp3-/- and 3 ng/ml for Asc-/- compared to 13 ng/ml 
for the WT, Figure 13A).  
It is well established that LPS stimulation (signal 1) leads to the expression of the 
Il-1β gene and the production of the pro-form of the cytokine (pro- IL-1β). Pro- IL-1β is 
then cleaved via caspase-1 to yield the mature active form of IL-1β [218].  The IL-1 ELISA 
detects the amount of both pro- IL-1β and mature IL-1β. Additional control experiments 
were performed in order to confirm that IL-1β detected in the supernatant is the mature 
secreted form of the cytokine. This was done to account for the possibility that Msme-
infected BMDCs might have been lysed via necrosis like processes such as pyroptosis or 
pyronecrosis, which were shown to be induced by inflammasome activation via caspase-1 
and ASC respectively [242]. Such events would result in the release of pro- IL-1β in the 
supernatant in which case the detected IL-1β would not entirely be of the mature form. To 
account for this possibility we measured the amount of pro-IL-1β in the supernatant via an 
ELISA kit (ebioscience) that only detects the pro-form of the cytokine. Figure 13D shows 
that no pro- IL-1β was detected in any supernatant for all conditions. This indicates that all 
the IL-1β in the supernatant is the mature secreted form of the cytokine. 
Our results demonstrated that the induction of IL-1β secretion in Msme-infected 
BMDCs requires ASC but is partially independent of NLRP3, and caspase-1/11. These 
results suggest that NLRP3 and caspases-1/11 are important for the secretion of some of 
the IL-1β but also other components are involved in this cytokine secretion. The NLRP3 
inflammasome has been extensively analyzed and is shown to be the main inflammasome 
responsible for the processing of pro- IL-1β into the mature form (IL-1β) by caspase-1 
upon infection with Mtb in macrophages (BMDMs and THP-1 cells). This pathway 
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involves ASC as an indispensible adapter molecule [108] [207] [211] [220] [243]. Our 
results suggest that Msme infection of BMDCs do activate the NLRP3 inflammasome  
leading to secretion of IL-1β but also other pathways that require ASC are involved in IL-
1β secretion. 
 
3.3.2 Msme induces apoptosis but not pyroptosis or pyronecrosis in dendritic cells. 
 Previous studies have shown that activation of NLR inflammasomes can lead to cell 
death via processes that resemble apoptosis or necrosis, called pyroptosis and pyronecrosis 
respectively. Pyroptosis is caspase-1-dependent and leads to the dimerization of ASC into 
pyropotosomes while pyronecrosis is independent of caspases but requires ASC [242]. 
Both pathways involve the loss of plasma membrane integrity resulting in the release of 
cytosolic proteins into the extracellular environment, which unlike apoptosis, maintains the 
integrity of the plasma membrane [248-250]. We previously showed that Msme incudes 
high levels of apoptosis of infected host macrophages and DCs (Figures 5, 6, and 11). Here 
we extend our analysis to test whether DCs infected with Msme undergo these forms of 
cells death. We infected WT, Nlrp3-/-, Asc-/-, and Casp1/11-/- BMDCs with Msme at MOI 
10:1 and analyzed the permeabilization of the cell plasma membrane via the detection of 
the cytosolic enzyme adenylate kinase (AK) in the supernatant, which would be released 
extracellularly (supernatant) if the cell membrane was compromised. In addition, we 
determined the percentage of apoptotic cells by quantifying the fraction of cells in the 
hypodiploid state via flow cytometry. First, the percentage of hypodiploid positive cells in 
Nlrp3-/-, Asc-/-, and Casp1/11-/- were all similar to the WT (approx. 75%) as shown in 
Figure 13C. These results agree with the previously reported data demonstrating that Msme 
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induces apoptosis in BMDCs (Figure 11) and also add to them by indicating that none of 
the examined inflammasome components are important for the induction of cell death via 
apoptosis. Furthermore, Msme did not lead to any increase in plasma membrane 
permeability of infected BMDCs as shown in Figure 13C where only a minor 1 to 2-fold 
increase in AK release was detected for all conditions compared to the cell lysis positive 
control, which showed a 24-fold increase in AK release with respect to the WT uninfected 
cells (WT/UI) (Figure 13C). These results highlight the absence of pyroptosis and 
pyronecrosis cell death in Msme-infected BMDCs. 
 
3.3.3 Msme and Mtb -induced secretion of IL-1β in macrophages is partially independent of 
caspase-1/11. 
Several groups have studied inflammasome activation and IL-1β secretion in 
response to Mtb infections in monocytes and macrophages [121] [220] [236-239] [244]. 
The secretion of IL-1β in Mtb-infected macrophages was shown to be dependent on ASC, 
NLRP3, and caspase-1 in vivo [104]. In addition, Mtb-infected BMDMs were shown to 
secrete small amounts of IL-1β in vitro ranging from 0.4 to 0.7 ng/ml as reported by several 
groups [238] [245] [237] [245] compared to the significantly larger amounts of IL-1β 
(approx. 3.8 ng/ml) in Mtb-infected BMDCs as we have shown in Figures 22 and 23. No 
analysis of IL-1β secretion in response to non-pathogenic mycobacteria has been reported 
in macrophages. Therefore, we sought to extend our analysis of the Msme and Mtb -
induced secretion of IL-1β to include macrophages in addition to our analysis in DCs.  In 
order to check the level of IL-1β secretion induced by Msme and Mtb in macrophages, we 
deprived WT and caspase-1/11-/- C57Bl/6 BMDMs from L cell-conditioned medium  
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Figure 14. Msme and Mtb -induced Secretion of IL-1β in macrophages is partially 
independent of caspase-1/11. BMDMs (A and C) and BMDCs (B and D) were derived from WT 
and caspase-1/11 mice and infected with Msme, Mtb H37Rv, or left uninfected (UI). The 
supernatants were harvested after 22 hours and the amount of secreted IL-1β (A and B) were 
detected by ELISA. The amounts of AK in the supernatant were measured via AK release 
colorimetric assay (C and D). The positive control (Pos Ctrl) indicates complete cell lysis via 
treatment with Triton-X. Shown are means and standard deviation of triplicate measurements of 
one representative experiment out of three. [Experiment performed in collaboration with Dr. Hana 
Abdalla]. 
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(LCCM) for 6 hours and infected them with virulent Mtb H37Rv and Msme at MOI 10:1 
for duration of 2 hours or left them uninfected. The cells were then washed and incubated 
in infection medium without LCCM and supplemented with gentamicin for an additional 
20 hours. The amounts of secreted IL-1β in the supernatant were measured via ELISA. WT 
and caspase-1/11-/- C57Bl/6 BMDCs were also infected with Msme and Mtb as previously 
described.  
WT BMDMs infected with Msme secreted large amounts of IL-1β (6.5 ± 0.3 ng/ml) 
while Casp1/11-/- BMDCs showed a significant decrease in IL-1β secretion upon infection 
with Msme (Figure 14A), which indicates that caspase-1/11is important for the secretion of 
IL-1β in macrophages. However, this decrease in IL-1β was only partial and the amount of 
secreted cytokine was still significant (approx. 2.7 ± 0.16 ng/ml) when compared to the 
uninfected control (Figure 14A). These results demonstrate that, like in BMDCs, the Msme-
induced IL-1β secretion in BMDMs is also partially independent of Casapse-1/11. In 
comparison, Mtb also showed the same pattern of Caspase-1/11-partially independent IL-
1β secretion in infected macrophages. The infection of WT BMDMs with Mtb induced the 
secretion of 3.4 ± 0.1 ng/ml IL-1β compared to a reduced but still significant secretion of 
1.6 ± 0.1 ng/ml IL-1β by Caspase1/11-/- BMDMs (Figure 14A). All detected IL-1β in the 
supernatant was of the secreted mature form since no cytosolic AK enzyme was detected in 
the supernatants of infected cells, which indicates that no cell lysis occurred as shown in 
Figure 14C. 
WT and Casp1/11-/- BMDCs infected in parallel with Msme and Mtb also showed 
the same pattern of IL-1β secretion. Msme induced the secretion of 7.8 ± 0.2 ng/ml and 3.2 
± 0.2 ng/ml IL-1β in WT and Casp1/11-/- BMDCs, respectively. Infections with Mtb also 
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induced the secretion of 3.8 ± 0.2 ng/ml and 1.5 ± 0.1 ng/ml IL-1β in WT and Casp1/11-/- 
BMDCs, respectively (Figure 14B). All detected IL-1β in the supernatant was of the 
secreted mature form since no cytosolic AK enzyme was detected in the supernatants of 
infected cells, which indicates that no cell lysis occurred as shown in Figure 14D. 
 
3.3.4. L cell-conditioned medium has an inhibitory effect on the Msme-induced IL-1β 
secretion in BMDMs.  
It was surprising that the amounts of IL-1β secreted by our Mtb-infected BMDMs 
(Figure 14A) are significantly higher than the amounts reported by serveral research groups 
in Mtb-infected BMDMs (0.4 to 0.7 ng/ml) [238] [245] [237] [245]. In addition, the 
Caspase-1/11-partially independent IL-1β secretion by Mtb-infected macrophages was not 
seen in those published studies. One explanation of the discrepancy between our results and 
published literature could be that we deprived our BMDMs from LCCM 18 hours prior to 
infection and kept them without LCCM during the course of infection while all other 
research groups did not include these deprivation conditions in their experiments [238] 
[237] [245]. To test this hypothesis, we pretreated fully differentiated BMDMs with 
different concentrations of LCCM (6% and 20%) or completely deprived them from this 
supplement 18 hours prior to infection with Msme, and kept them under these same 
conditions during infection. Cells were infected at MOI 10:1 for duration of 2 hours, 
washed, then incubated in media with gentamicin for an additional 20 hours. The amounts 
of secreted IL-1β in the supernatants were measured via ELISA. Msme-infected BMDMs 
that were completely deprived from LCCM secreted approximately 7.6 ± 0.8 ng/ml IL-1β 
compared to 5.4 ± 0.4 ng/ml and 2.6 ± 0.2 ng/ml for the 6% and 20% LCCM-supplemented 
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BMDMs, respectively (Figure 15A). All detected IL-1β in the supernatant was of the 
secreted mature form since no cytosolic AK enzyme was detected in the supernatants of 
infected cells, which indicates that no cell lysis occurred as shown in Figure 15B. These 
results support our hypothesis by demonstrating that LCCM has an inhibitory effect on the 
capacity of BMDMs to secrete IL-1β upon infection with mycobacteria.  
LCCM is a source of macrophage colony-stimulating factor (M-CSF), which is 
essential for the differentiation of monocytes into macrophages [246] [247]. It was 
therefore logical to ask whether it is the M-CSF in LCCM that is responsible for this 
inhibitory effect on IL-1β secretion in BMDMs. To test this hypothesis, we measured the 
exact amount of M-CSF in the LCCM that was used in the BMDM infection experiments 
(presented in Figure 15A) by ELISA and repeated the infection of BMDMs with Msme 
using recombinant mouse M-CSF at concentrations matching the percentages of LCCM 
used in the previous experiment (presented in Figure 15A). The LCCM we used contained 
approximately 158 ng/ml M-CSF. Therefore, we pretreated fully differentiated BMDMs 
with 9.48 ng/ml and 31.6 ng/ml recombinant M-CSF or completely deprived them from M-
CSF (as equivalents for the 6%, 20%, and no LCCM, respectively) for 18 hours then 
infected with Msme as previously described. The same M-CSF conditions were maintained 
throughout the 22 hours infection. We then measured the amounts of secreted IL-1β by 
ELISA. There was no significant difference in Msme-induced IL-1β secretion between 
BMDMs deprived from LCCM and the ones supplemented with 9.48 ng/ml M-CSF. 
However, BMDMs supplemented with 31.6 ng/ml M-CSF showed a slightly significant 
decrease in IL-1β secretion (approx. 5 ng/ml) compared to BMDMs deprived of M-CSF 
(approx. 7.4 ng/ml) (Figure 15C). These results suggest that M-CSF plays a small role in  
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Figure 15. L cell-conditioned medium has a inhibitory effect on the Msme-induced IL-1β secretion 
in BMDMs. A. BMDMs were derived from WT mice then supplemented with 6%, 20%, or left without L 
cell-conditioned medium (LCCM) for 18 hours then infected with Msme at MOI 10:1 left uninfected (UI). 
The supernatants were harvested after 22 hours and the amount of secreted IL-1β were detected by ELISA. 
The amounts of AK in the supernatant were measured via AK release colorimetric assay (B) The positive 
control (Pos Ctrl) indicates complete cell lysis via treatment with Triton-X. C. BMDMs derived from WT 
mice were supplemented with 9.48 ng/ml, 31.6 ng/ml, or left without recombinant macrophage colony-
stimulating factor (M-CSF) for 18 hours then infected with Msme at MOI 10:1 left uninfected (UI). The 
supernatants were harvested after 22 hours and the amount of secreted IL-1β were detected by ELISA. 
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the inhibition of the Msme-induced IL-1β secretion in BMDMs. However, The comparison 
of these results (Figure 15C) with the effect of complete LCCM on IL-1β secretion (Figure 
15A) suggests that M-CSF it is not the only components of LCCM that is responsible for 
this inhibition 
 
3.3.5 The IL-1 receptor is not required for Msme-mediated IL-1β secretion and has no role 
in apoptosis induction in dendritic cells. 
We further sought to investigate whether signaling via the IL-1 receptor is required 
for the Msme-induced secretion of IL-1β and to check whether IL-1R signaling is involved 
in the Msme-induced apoptosis in DCs. We infected WT and Il-1r deficient (Il-1r -/-) 
BMDCs with Msme as previously described. We also pre-treated WT BMDCs with the 
drug Anakinra, an antagonist of IL-1R, and infected those cells with Msme as well. We 
then measured the amounts of secreted IL-1β in the supernatants and quantified the number 
of apoptotic cells via the hypodiploid cytometric assay. The lack of IL-1R did not have any 
effect on the Msme-induced secretion of IL-1β. This indicates that IL-1β secretion does not 
have a positive autocrine feedback via IL-1R signaling. Furthermore, the lack of IL-1R did 
not have any effect on the apoptotic response induced by Msme in dendritic cells. Msme 
infection in both WT and Il-1r-/- BMDCs induced similar levels of apoptosis (approx. 75% 
hypodiploid positive cells) (Figure 16B). Concurrently, treatment of WT BMDCs with 
Anakinra did not have any effect on the induction of apoptosis by Msme in DCs since both 
Anakinra-treated and untreated BMDCs showed similar levels of apoptosis upon infection 
with Msme (approx. 68% hypodiploid positive cell). These results suggest that signaling of 
IL-1β via IL-1R is not involved in the induction of apoptosis in Msme-infected DCs. 
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Figure 16. The IL-1 receptor is not required for Msme-induced IL-1β secretion and has 
no role in apoptosis induction. A and C. BMDCs from WT and Il-1r deficient (Il-1r -/-) mice 
were infected with Msme. B and D. BMDCs from WT mice were treated with Anakinra (IL-
1R antagonist) or left untreated (UT) then infected with Msme or left uninfected (UI). The 
amount of secreted IL-1β in the supernatants were measured 22 hours after infection by ELISA 
(A and B). The percentage of apoptotic cells was also measured 22 hours post infection via the 
hypodiploid cytomteric assay (C and D). Shown are means and standard deviation of triplicate 
measurements of one representative experiment out of three. 
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3.3.6 Msme-induced IL-1β secretion in dendritic cells is independent of caspases-3, -8, and 
-9. 
As previously stated, in vivo Mtb infection studies have implicated the presence of 
caspase-1-independent production of IL-1β in contrast to caspase-1-dependent IL-1β 
production in BMDMs infections in vitro, which suggests the involvement of cell types 
other than macrophages such as DCs in the production of IL-1β [104].We have shown that 
decreased (compared to WT) but significant amount of secreted IL-1β was independent of 
caspase-1/11 in BMDCs infected with Msme (Figure 13A). Therefore, it is possible that 
other protease(s) might be involved in the processing of pro- IL-1β and the secretion of 
mature IL-1β. To test this hypothesis we checked for the involvement of caspases other 
than caspase-1 and-11 in the production of IL-1β. We pre-treated Casp-1/11-/- BMDCs with 
a general pan caspase inhibitor (z-vad-fmk), caspase-3 inhibitor, caspase-8 inhibitor, 
caspsase-9 inhibitor, caspase inhibitor chemical analog (negative control), or left the cells 
untreated for duration of 4 hours then infected them with Msme for 2 hours. We then 
washed the cells and incubated them in infection medium supplemented with gentamicin 
while maintaining the same concentrations of inhibitors in the medium. The amounts of 
secreted IL-1β were measured in the supernatant via ELISA. Interestingly, the general pan 
caspase inhibitor further reduced the secretion of IL-1β in Casp1/11-/- BMDCs to 1.9 ± 0.1 
ng/ml compared to the untreated cells (3.4 ± 0.3 ng/ml) upon infection with Msme (Figure 
17A). This significant decrease in IL-1β secretion indicates the involvement of a caspase(s) 
other than caspase-1 in the production of IL-1β. The inhibition of caspases-3, -8, or -9 did 
not result in any significant decrease in the amount of secreted IL-1β (Figure 17A). All the 
 
 



































Figure 17. Msme-induced IL-1β secretion is independent of caspases-3, -8, and -9. BMDCs 
were pre-treated with capase-3 inhinbitor (casp 3 inh), capase-8 inhinbitor (casp 8 inh), capase-
9 inhinbitor (casp 9 inh), a general caspase inhibitor (pan casp inh), inactive chemical analog 
(casp inh – ctrl) or left the cells untreated (UT) then infected them with Msme for duration of 2 
hours. The untreated cells were also left uninfected (UT /UI). The cells were then washed and 
incubated in media supplemented with gentamicin and the same concentrations of inhibitors. 
Culture supernatants where collected 20 hours later and assayed for the amounts of secreted 
IL-1β by ELISA (A) or the amounts of AK released by the AK release colorimetric assay (B). 
The positive control (Pos Ctrl) indicates complete cell lysis via treatment with Triton-X. 
Shown are means and standard deviation of triplicate measurements of one representative 
experiment out of three. 
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IL-1β detected in the supernatant was of the secreted mature form since no cytosolic AK 
enzyme was detected in the supernatants of infected cells, which indicates that no cell lysis 
occurred as shown in Figure 17B. These results demonstrate the involvement of a caspase 
other than caspase-1 in the production of IL-1β in Msme-infected BMDCs. They further 
extend the analysis and eliminate three main caspases, -3, -8, and -9 from the pool of 
possible caspases that might be involved in the production of IL-1β in Msme-infected 
BMDCs. 
 
3.3.7 Msme-induced IL-1β secretion in dendritic cells is independent of Cathepsins B, L, S 
and Calpain. 
 The cysteine proteases cathepsins are reported to be involved inflammasome 
activation and IL-1β secretion. Previous studies have shown that inflammasome activation 
and subsequent secretion of IL-1β were dependent on Cathepsin B (CatB) and NLRP3 
inflammasome activation via P2X7 receptor stimulated by the acute-phase protein serum 
amyloid A (SAA) [251-253]. The release of cathepsin B and the production of ROS were 
also reported to be involved in Mkan-induced inflammasome activation [220]. Furthermore, 
CatB, cathepsin L (CatL), and cathepsin S (CatS) along with NLRP3 were also shown to be 
required for IL-1β secretion during inflammatory Colitis in mice [252]. CatB inhibition 
also attenuated the secretion of IL-1β from Nlrp3 and Asc deficient microglia [252]. 
Another protease, calpain, was also reported to be involved in the processing of IL-1-α in 
mice and BMDCs via a caspase-1-independent pathway [254]. We therefore extended our 
analysis of the caspase-1/11-independent IL-1β secretion in Msme-infected BMDCs to test 
whether cathepsins (CatB, CatS, and CatL) and calpain are involved in the production of  































Figure 18. Msme-induced IL-1β secretion is independent of Cathepsins B, L, S and 
Calpain. BMDCs were pre-treated with inhibitor of Cathepsins B, S, and L (cathepsin 
(B,L,S0 inh) or left untreated for duration of 4 hours then infected them with Msme at MOI 
10:1 duration of two hours. The untreated cells were also left uninfected (UT /UI). Cells 
were then washed and incubated in infection medium with gentamicin for an additional 20 
hours while maintaining the same concentration of inhibitor in the media. The amounts of 
secreted IL-1β were measured in the supernatant after 20 hours by ELISA. Shown are 
means and standard deviation of triplicate measurements of one representative experiment 
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the cytokine. We pre-treated BMDCs with inhibitor of cathepsins B, S, and L, inhibitor of 
calpain, or left them untreated for duration of 4 hours then infected them with Msme at 
MOI 10:1 as previously described for duration of 2 hours. The cells were then washed and 
incubated in infection medium with gentamicin for an additional 20 hours while 
maintaining the same concentration of inhibitors in the media. As shown in Figure 18, the 
amounts of secreted IL-1β in the supernatant were similar for all conditions compared to 
untreated Msme-infected cells (7-7.8 ng/ml, p > 0.05). Our results indicate that none of the 
examined proteases (CatB, CatS, CatS, and calpain) were involved in the production of IL-
1β in Msme-infected BMDCs (Figure 18). 
 
3.3.8 Characterization of the caspase-1/11-independent IL-1β secretion in dendritic cells. 
A recent study has shown that in addition to the NLRP3-caspase-1-dependent IL-1β 
secretion in BMDMs and BMDCs, there is a caspase-8 pathway that promotes IL-1β 
precursor maturation and secretion independently of inflammasome activation [255]. This 
NLRP3-caspase-1-independent caspase-8-dependent production of IL-1β was demonstrated 
to be independent of ASC. Both the NLRP3-caspase-1-dependent and the caspase-8-
dependent-ASC-independnt processing of IL-1β relied on RIP3 kinase activation in 
response to the inhibition of inhibitors of apoptosis (IAP) in macrophages and DCs [255] 
[256]. Another study revealed dectin-1 as an extracellular pathogen sensor involved in the 
induction and processing of IL-1β via a non-canonical caspase-8 inflammasome [257]. 
These recently published reports prompted us to re-examine the involvement of caspase-8 
in IL-1β secretion and extend our analysis by examining the involvement of dectin-1 in the  
 





Figure 19. The caspase-1-independent IL-1β secretion is independent of dectin-1. WT (A) and 
caspase-1/11-/- (B) BMDCs were pre-treated with mouse anti-dectin-1 neutralizing antibody (α-dectin-1), 
caspase-8 inhibitor (casp8 inh), both inhibitors, or left untreated (UT) then infected with Msme at MOI 
10:1 for duration of two hours. The untreated cells were also left uninfected (UT /UI). Cells were then 
washed and incubated in infection medium with gentamicin for an additional 20 hours while maintaining 
the same concentration of inhibitors in the media. The amounts of secreted IL-1β were measured in the 
supernatant after 20 hours by ELISA. Shown are means and standard deviation of triplicate 
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production of the cytokine. Therefore, we pre-treated WT and caspase-1/11 deficient 
BMDCs with anti-dectin-1 neutralizing and caspase-1/11 deficient BMDCs with anti-
dectin-1 neutralizing antibody (α-dectin-1), caspase-8 inhibitor, both α -dectin-1 and 
caspase-8 inhibitor, inactive chemical analog, or left them untreated for 4 hours then 
infected them with Msme as previously described for duration of 2 hours followed by 20 
hours incubation in infection medium with gentamicin and same concentrations of 
neutralizing antibodies and inhibitory chemicals. WT BMDCs infected with Msme showed 
similar levels of secreted IL-1β among all treatment conditions (approx. 7-7.8 ng/ml) 
compared to the untreated (UT) Msme-infected cells (8.2 ng/ml) (Figure 19A). None of the 
treatments showed a significant decrease in IL-1β secretion compared to the UT control (p 
>0.05) (Figure 19A). Concurrently, Casp1/11-/- Msme-infected BMDCs secreted similar 
amount of IL-1β, except that the amounts of cytokine were overall decreased (approx. 3-3.4 
ng/ml) across all conditions compared to WT BMDCs (Figure 19B). This decrease in IL-1β 
secretion was expected since IL-1β secretion is partially dependent on caspase-1/11 as was 
previously demonstrated (Figure 13A). These results failed to reveal any role of caspase-8 
or dectin-1 in the secretion of IL-1β whether it is casapse-1-dependent or -independent.  
Our previously described results showed that BMDCs deficient in Asc were completely 
defective in IL-1β secretion upon infection with Msme (Figure 13A). Indeed, we confirmed 
that all IL-1β processing and secretion in Msme-infected BMDCs were dependent on 
inflammasome activation, specifically ASC-dependent inflammasome activation. We also 
demonstrated that the IL-1β secretion is only partially dependent on NLRP3 in Msme-
infected BMDCs (Figure 13A). In order to further characterize the caspase-1/11- 
 







Figure 20. Characterization of the caspase-1/11-independent IL-1β secretion in dendritic cells. WT and 
Nlrp3-/- BMDCs were pre-treated with capase-1 inhinbitor (casp 1 inh), general caspase inhibitor (pan casp inh), 
inactive chemical analog (Casp Inh Neg Ctrl) or left untreated (UT) then infected with Msme for duration of 2 
hours. The untreated cells were also left uninfected (UT /UI). The cells were then washed and incubated in 
media supplemented with gentamicin and the same concentrations of inhibitors. Culture supernatants where 
collected 20 hours later and assayed for the amounts of secreted IL-1β by ELISA. Shown are means and 
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-independent IL-1β secretion, we used WT and Nlrp3 -/- BMDCs and pre-treated them with 
caspase-1 inhibitor, pan-caspase inhibitor (z-vad-fmk) or left them untreated, then infected 
them with Msme. Both Msme-infected WT and Nlrp3-/- cells  
treated with caspase-1 inhibitor secreted the same amounts of IL-1β (3.8 ± 0.2 ng/ml and 
3.9 ± 0.1 ng/ml respectively) (Figure 20). These results demonstrate that the caspase-1/11-
independent IL-1β production in Msme-infected BMDCs is independent of NLRP3.  
 
3.3.9 Msme-induced IL-1β secretion in dendritic cells is partially dependent on AIM2 but 
independent of NLRP6, NLRP10, NLRP12, and IPAF. 
 We have shown that IL-1β secretion in Msme-infected BMDCs was only partially-
dependent on NLRP3 inflammasome component (Figure 13A and 21A). However, IL-1β 
Secretion was strictly dependent on ASC (Figure 13A and 21A). The indispensible 
involvement of ASC suggests that there is another inflammasome involved in the 
production of IL-1β since ASC is a major adaptor protein that is common to several NLR 
family member inflammasomes (NLRP1, NLRP2, NLRP3, IPAF, NLRP6, NLRP10, 
NLRP12) as well as the PYHIN family member AIM2 [210]. In order to examine the 
involvement of another inflammasome other than NLRP3 in the secretion of IL-1β, we 
used BMDCs from Asc-/-, Nlrp3-/-, Ipaf-/-, Nlrp6-/-, Nlrp10-/-, Nlrp12-/-, Aim2-/-, and WT mice 
and infected them with Msme as previously described. The amounts of IL-1β secreted in 
the supernatant were measured via ELISA. The levels of IL-1β secreted by BMDCs 
deficient in IPAF (12.1 ± 0.6 ng/ml), NLRP6 (9.5 ± 0.6 ng/ml), NLRP10 (11.1 ± 1.4 ng/ml), 
and NLRP12 (9.9 ± 1.1 ng/ml) were similar to the level of IL-1β secreted by WT BMDCs 
(11 ± 0.7 ng/ml) (p > 0.05, Figure 21A). The secretion of IL-1β by Msme-infected Nlrp3  
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Figure 21. Msme-induced IL-1β secretion is partially dependent on AIM2 but 
independent of NLRP6, NLRP10, and NLRP12. BMDCs from Asc-/-, Nlrp3-/-, Ipaf-/-, 
Nlrp6-/-, Nlrp10-/-, Nlrp12-/-, WT mice (A), and Aim2-/- BMDCs (B) were infected with 
Msme or left uninfected (UI) for two hours then washed and incubated in media 
supplemented with gentamicin. The supernatants were collected 20 hours later and 
assayed for the amounts of secreted IL-1β by ELSA. Shown are means and standard 
deviation of triplicate measurements of one representative experiment out of three. 
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deficient BMDCs was expectedly decreased (6.1 ± 0.9 ng/ml) and completely abolished in 
Asc deficient BMDCs since no significant amounts of IL-1β were secreted compared to the 
uninfected control (UI)as was observed in previous experiments (Figure 13A). These 
results eliminate NLRP6, NLRP10, NLRP12, and IPAF from the pool of possible NLR 
family inflammasomes that might have been involved in the secretion of IL-1β in BMDCs.  
Interestingly, the absence of AIM2 had a very significant effect on the levels of 
Msme-induced secretion of IL-1β in BMDCs. As shown in Figure 21B, Aim2-/- BMDCs 
secreted only 3.7 ± ng/ml IL-1β upon infection with Msme compared to WT cells, which 
secreted 12.3 ± 1.3 ng/ml IL-1β. This significant decrease in cytokine secretion 
demonstrates the involvement of AIM2 inflammasome in the secretion of IL-1β in Msme-
infected BMDCs. All previous studies only reported the involvement of NLRP3 in the 
inflammasome response against Mtb in macrophages and dendritic cells [104] [220]. This 
is the first time that AIM2 is implicated in the inflammasome activation in response to 
infection with a mycobacterial species in dendritic cells. 
 
3.3.10 AIM2 plays a role in the IL-1β secretion by dendritic cells infected with non-
pathogenic and attenuated but not virulent mycobacteria. 
 Thus far, our analysis of Msme-induced IL-1β production in mouse BMDCs has 
shown that IL-1β is abundantly secreted and that this secretion was indispensible of ASC, 
and partially dependent on NLRP3 and caspase-1/11. The caspase-1/11-independent 
secretion of IL-1β was also shown to be independent of NLRP3. Our analysis revealed the 
partial involvement of AIM2 inflammasome component in the secretion of mature IL-1β in 
Msme-infected BMDCs. This involvement of AIM2 has not been examined in vitro or in 
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vivo. This is the first time that AIM2 is implicated in the secretion of IL-1β in response to 
infections with a mycobacterial species. Several studies addressed the capacity of different 
mycobacterial species to activate the inflammasome and induce the secretion of IL-1β in 
macrophages but no detailed analysis was performed on DCs. Studies involving Mtb 
infections have shown that virulent Mtb H37Rv and attenuated Mtb H37Ra induced 
NLRP3, ASC, and caspase-1-dependent inflammasome activation and subsequent IL-1β 
secretion in human macrophage cell line THP-1 and in primary mouse BMDMs [104] 
[220]. These studies have also shown that ASC but not NLRP3 nor caspase-1 are important 
for the host defense against Mtb in vivo despite their importance in vitro [218]. Other 
studies showed that the NLRP3/ASC inflammasome contributes to casapse-1 activation 
and IL-1β secretion during Mkan infection of THP-1 cells [220]. Facultative-pathogenic 
BCG fails to induce the secretion of mature IL-1β in macrophages and DCs due to its 
inability to process pro- IL-1β to its mature form [257]. We therefore examined the 
involvement of AIM2 in the production of IL-1β in response to infections with a multitude 
of virulent, attenuated, and non-pathogenic mycobacterial species in DCs. We used Aim2-/- 
and WT BMDCs and infected them with virulent Mtb H37Rv, attenuated Mtb H37Ra, 
Mkan, Mfort, Msme, and F. tularensis Live Vaccine Strain (LVS). F.tularensis was shown 
to induce the secretion of IL-1β via AIM2-dependent pathway in macrophages and DCs 
[217] [258]. Cells were infected for 2 hours then washed and incubated in media with 
gentamicin for additional 20 hours as previously described. The amounts of secreted IL-1β 
were quantified by ELISA. Interestingly, All mycobacterial species, except virulent Mtb 
H37Rv, showed a significant decrease in the secretion of IL-1β compared to the WT 
(Figure 22). As expected, the Francisella control (LVS) did not induce any significant  
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Figure 22. AIM2 plays a role in the IL-1β secretion by dendritic cells infected with non-
pathogenic and attenuated but not virulent mycobacteria. WT and Aim2-/- BMDCs were 
infected with Francisella Live vaccine strain (LVS), Msme, Mfort, Mkan, Mtb H37Rv, Mtb 
h37Ra, or left uninfected (UI) for duration of 2 h then washed and incubated in media with 
gentamycin. The supernatants were collected 20 h later and assayed for the amounts for 
secreted IL-1β by ELISA. Shown are means and standard deviation of triplicate 
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secretion of IL-1β (Figure 22) since it depends primarily on the AIM2 inflammasome for 
the production of mature IL-1β [211] [258]. The capacity of virulent Mtb H37Rv strain to 
induce the secretion of IL-1β in BMDCs was not undermined by the lack of AIM2 as was 
expected since a recent study in our lab demonstrated that the secretion of IL-1β in virulent 
Mtb-infected BMDCs indispensably requires NLRP3 [259]. In this study, Nlrp3-/- BMDCs 
infected with virulent Mtb failed to secrete any significant amounts of IL-1β. In our 
analysis, Mtb H37Rv induced the secretion of approximately 3.8 ng/ml IL-1β in WT 
BMDCs compared to a similar 3.7 ng/ml secretion in Aim2-/- BMDCs (Figure 22). The 
attenuated Mtb H37Ra-induced IL-1β secretion in BMDC showed the least dependence on 
AIM2 among all examined facultative-pathogenic and non-pathogenic mycobacteria since 
the secretion of IL-1β induced by H37Ra only decreased from 5.3 ± 0.6 ng/ml in WT to 2.9 
± 0.3 ng/ml in Aim2-/- BMDCs compared to higher decreases in other mycobacterial species 
(Figure 22). Our results suggest an evolutionary role for AIM2-dependent inflammasome 
activation and IL-1β secretion in mycobacteria-infected DC where non-pathogenic and 
attenuated species of mycobacteria are capable of engaging another inflammasome in 
addition to NLRP3 upon infection of host DCs. 
 
3.3.11 IFN-β is important for the AIM2-dependent Msme-induced IL-1β secretion in 
dendritic cells. 
AIM2 inflammasome activation was whown to be dependent on type I interferon 
family member interferon-β (IFN-β) in BMDMs but this dependence was only partial in 
BMDCs [217].  This was reported in studies where Francisella-infected BMDMs and 
BMDCs deficient in type I interferon receptor (Ifnr-/-) showed total reduction in the 
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secretion of IL-1β from infected BMDMs but only partial reduction of the cytokine in 
infected BMDCs of [211]. IFN-β was also shown to act upstream of AIM2 leading to 
activation of the AIM2 inflammasome and subsequent activation of casapase-1 and 
processing of pro- IL-1β into the mature secreted form [258] [260] [261]. Conversely, IFN-
β was not shown to have any effect on other ASC dependent inflammasomes such as 
NLRP3, NLRP6, and NLRP12 [221]. IFN-β was also shown to play a role in the inhibition 
of Il-1β gene expression in THP-1 cells. Mtb-induced IL-1β production was shown to be 
suppressed by IFN-β in THP-1 cells but not monocytes [221]. This suppression of mature 
IL-1β production was shown to be due to lower levels of pro- IL-1β as a result of IFN-β 
induced inhibition of l1-1β gene expression [221]. These studies of IFN-β inhibition of l1-
1β expression only involved macrophages and did not examine this newly found role of 
IFN-β in DCs. Therefore, we examined the involvement of IFN-β and its role in AIM2-
mediated secretion of IL-1β in BMDCs upon infection with virulent Mtb and non-
pathogenic Msme. We pre-treated WT and Aim2-/- deficient BMDCs with anti-mouse IFN-β 
neutralizing antibody (10 µg/ml) or left untreated (UT) for duration of 4 hours, then 
infected them with Mtb, Msme, and Francisella LVS vaccine strain (positive control) for 
two hours as previously described. We then washed the cells and incubated them in 
infection media supplemented with gentamicin and the same amount of anti-mouse IFN- β. 
The amounts of secreted IL-1β in the supernatants were measured using ELISA (Figure 22). 
The anti-mouse IFN-β (Abcam # ab24324) has been reported in published studies to be 
specific and effective for the neutralization of mouse IFN-β in primary macrophages and 
RAW cells [262]. The lack of AIM2 in Mtb-infected BMDCs (Aim2-/-) did not have any 
effect on the secretion of IL-1β confirming that the production of IL-1β in response to Mtb  
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Figure 23. IFN-β is important for the AIM2-dependent Msme-induced IL-1β secretion in 
BMDCs. WT and Aim2-/- BMDCs were pre-treated with anti-mouse IFN-β neutralizing antibody 
(10 µg/ml) or left untreated for duration of 4 hours then infected them with Francisella Live 
vaccine strain (LVS), Msme, virulent Mtb H37Rv (Rv), or left uninfected (UI) for duration of 
two hours then washed and incubated in media with gentamycin. The supernatants were 
collected 20 hours later and assayed for the amounts for secreted IL-1β by ELSA. Shown are 
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infections of DCs does not involve the AIM2 inflammasome (Figure 22). Indeed, the 
blocking of IFN-β in Mtb-infected WT and Aim2-/- BMDCs had no effect on the production 
of IL-1β (Figure 23). However, our results indicated that the blocking of IFN-β in Msme-
infected cells significantly but only partially reduced the amount of secreted IL-1β in WT 
BMDCs (9.1 ± 0.9 ng/ml without anti-IFN-β and 6 ± 0.3 ng/ml with anti IFN-β (Figure 23). 
Msme infection of Aim2-/- BMDCs treated with anti-IFN-β antibody or left untreated (UT), 
induced the secretion of similar levels of IL-1β (approx. 3.9 ng/ml and 4.3 ng/ml, Figure 
23), which demonstrates that IFN-β inhibition does not have any additive effect on Msme-
infected Aim2-/- BMDCs. These results agree with previous studies in Francisella where 
infected macrophages and DCs showed that IFN-β is only involved in the activation of 
AIM2 inflammasome but not NLRP3, NLRP6, and NLRP12 inflammasomes. Our results 
underscore the important role of IFN-β in the AIM2-dependent IL-1β secretion in BMDCs 
upon infection with non-pathogenic mycobacterial species Msme. 
 
3.3.12 Discussion. 
 IL-1β is a very important proinflammatory cytokine whose production and secretion 
play an important role in the host IR against bacterial and viral pathogens [207] [212] [218] 
[237]. Mice lacking the Il-1β or IL-1 receptor (Il-1R) genes are more susceptible to 
infections with Mtb [116] [117] [122] [218] [219]. Inflammasome activation leads to 
secretion of IL-1β, which is well established as an important player in the host defense 
against Mtb infections in macrophages in vitro [104]. This inflammasome-dependent IL-1β 
secretion is not required for the production of IL-1β in vivo [218]. This difference in IL-1β 
production requirements between in vivo and in vitro macrophage infections suggests that 
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cell types other than macrophages are involved in the processing and secretion of IL-1β. 
Our analysis focused on IL-1β secretion in response to mycobacterial infections of DCs, 
which to date are poorly studied in terms of inflammasome activation and IL-1β secretion. 
We primarily used the non-pathogenic mycobacteria Msme in our study since Msme 
induces a stronger innate and proinflammatory IR in host macrophages and DCs when 
compared to a weaker host IR against facultative pathogenic mycobacteria as was 
demonstrated in our previous results (Figures 5, 6, and 11).  
Our analysis in BMDCs revealed that Msme induces the secretion of IL-1β via an 
ASC-dependent and a NLRP3-casapse-1/11-partially independent pathway (Figure 13). 
Msme, as shown in our results, as well as Mtb [207], have the capacity to trigger both 
signals that are required for the production of  IL-1β (section 1.5.1.2) without the need for 
additional triggers.  
Furthermore, the partial dependence of Msme-induced secretion of IL-1β on 
caspase-1/11 (Figure 13A) was also demonstrated in Mtb-infected BMDCs [259]. These 
findings suggest the involvement of other protease(s) in the processing and secretion of IL-
1β. This caspase-dependent but casapase-1-indendent secretion of IL-1β is shown to be 
independent of NLRP3 (Figure 20). The capacity of a general caspase inhibitor to further 
reduce the amount of secreted IL-1β in Casp-1/11-/- BMDCs (Figure 17) suggests that such 
protease is a member of the caspase family. Our extended analysis further eliminated the 
involvement of caspases-3, -8, -9, dectin-1, as well as CatB, CatL, CastS, and Calpain in 
the Msme-induced secretion of IL-1β in BMDCs (Figures 18 and 19). Dectin-1 was 
reported to induce the secretion of IL-1β via a non-canonical casapse-8 inflammasome-
dependent pathway, with dectin-1 acting as an extracellular sensor for pathogens [257]. 
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This non-canonical inflammasome activation requires extracellular pathogen recognition, is 
independent of pathogen internalization, and does not require caspase-1 for the processing 
of pro- IL-1β [257].  
The processing of pro- IL-1β into the mature form in DCs was dependent on 
canonical inflammasome activation and caspase-1 activity for Mtb-infected cells, but 
dependent on processing via caspase-8 in M. leprae infections [257]. This suggests that 
different mycobacterial species invoke different pathways for the induced secretion of IL-
1β in the host. Our results demonstrated that infection of BMDCs with Msme, similar to 
Mtb infections [104], does not depend on dectin-1 mediated activity of caspase-8. RIP3 was 
suggested to be required for optimal NLRP3-caspase-1 inflammasome-dependent and –
independent IL-1β processing. NLRP3-caspase-1-dependent processing of IL-1β was 
shown to rely on RIP3 kinase activation in response to the inhibition of inhibitors of 
apoptosis (IAP) in macrophages and DCs [255]. In addition, RIP3 signaling can promote 
mitochondrial ROS production. This ROS generation is proposed to facilitate NLRP3-
dependent IL-1β processing. We have shown that ROS generation and accumulation is high 
in Msme-infected BMDCs (Figure 12) in contrast with Mtb, which is reported to negatively 
affect ROS generation and accumulation in host cells [163]. This increased ROS 
accumulation provides one explanation for the high levels of IL-1β secretion in Msme-
infected BMDCs. Furthermore, the inability of non-pathogenic mycobacteria such as Msme 
to inhibit host cell apoptosis as demonstrated in Figures 11 and 13B could provide another 
explanation for this increased IL-1β secretion in DCs. Therefore, we hypothesized that 
Msme does not induce the expression of inhibitors of apoptosis (IAP) in infected cells, 
which in turn leads to increased RIP3 kinase activity and subsequent optimal NLRP3-
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caspase-1 inflammasome-dependent and –independent IL-1β processing. In this hypothesis, 
IAPs would act upstream of caspase-3-dependent apoptosis induction since Msme-induced 
apoptosis in BMDCs and BMDMs was shown to be dependent on casapase-3 (Figure 8). 
We were unable to unveil the other caspase(s) that could be involved in the processing of 
IL-1β. Further studies using RNA silencing approach (siRNA) to knockdown individual 
caspases in BMDCs are needed to check the involvement of these caspases in IL-1β 
secretion in Msme-infected BMDCs. Our inability to knockdown genes in BMDCs for 
technical reasons was a limiting factor in our analysis. 
We also demonstrated that Msme induces host DCs cell death via apoptosis but not 
necrosis, pyroptosis, or pyronecrosis (Figures 11, 13B, and 13C). This caspase-3-dependent 
apoptotic response was not dependent on any inflammasome component (NLRP3, ASC, 
caspase-1, and AIM2) (Figure 13B), and the secretion of IL-1β in Msme-infected BMDC 
does not depend on caspase-3. These findings suggest that there is no direct link between 
inflammasome activation / IL-1β secretion and apoptosis induction. 
The NLRP-partially-dependent but –ASC-dependent IL-1β secretion by Msme-
infected BMDCs (Figure 13A) suggested the involvement of another PRR that can interact 
with ASC leading to the processing of IL-1β. Our analysis involving a series of ASC-
interacting NLRs (NLRP6, NLRP10, NLRP12, and IPAF) and PYHIN (AIM2) proteins 
revealed the involvement of AIM2 but not the aforementioned NLRs in the secretion of IL-
1β in Msme-infected BMDCs (Figure 21). This is first time that the recently described 
AIM2 inflammasome is implicated in mycobacteria-induced IL-1β secretion in dendritic 
cells. AIM2 is a member of the PYHIN protein family, a family of IFN-inducible proteins 
[208] [211] [217], and is localized in the cytoplasm. AIM2 is a cytosolic PRR that binds 
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dsDNA via HIN200 domain interaction and engages the adapter protein ASC via PYD-
PYD domains interaction. ASC then recruits and activates caspase-1 via CARD-CARD 
domain interaction leading to the processing of pro- IL-1β into the mature form [211]. It is 
reported that AIM2 regulates caspase-1 activation and IL-1β secretion in response to 
dsDNA from a variety of viruses, bacteria, and even from the host [211]. It has also been 
shown that AIM2 is activated in response to Francisella infections [217]. Francisella 
escapes into the cytosol of infected dendritic cells where AIM2 senses its dsDNA. This 
recognition leads to the activation of AIM2 inflammasome via ASC-dependent pathway 
leading to activation of caspase-1, which leads to rapid release of proinflammatory IL-1β 
and rapid cell death via pyroptosis [217]. Our assessment of the involvement of AIM2 in 
IL-1β secretion in DCs demonstrated that AIM2 is partially involved in the production of 
IL-1β in Msme-infected BMDCs (Figures 22 and 23). Indeed, the involvement of AIM2 in 
the production of IL-1β in response to infection with a multitude of virulent, attenuated, 
and non-pathogenic mycobacterial species also showed a role for AIM2 in the secretion of 
IL-1β induced by Mfort, Mkan and attenuated Mtb H37Ra in DCs. AIM2 was shown to 
have no importance in virulent Mtb-induced secretion of IL-1β in DCs (Figure 22). This 
AIM2-independent Mtb-induced IL-1β secretion in BMDCs agrees with a recently publised 
study in our lab [259], which demonstrated that the production of IL-1β in Mtb-infected 
BMDCs is strictly dependent on NLRP3. The attenuated Mtb H37Ra induced IL-1β 
secretion in BMDC showed the least dependence on AIM2 among all tested facultative-
pathogenic and non-pathogenic mycobacteria. Our results suggest an evolutionary role for 
AIM2-dependent inflammasome activation and IL-1β secretion in mycobacteria-infected 
DCs, whereas non-pathogenic and attenuated species of mycobacteria are capable of 
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engaging another inflammasome in addition to NLRP3 upon infection of host DCs. This 
high inflammatory response involving the activation of more than one inflammasome type 
is beneficial to the host making it more resistant to such infections. In contrast, virulent Mtb 
is suggested to have evolved to possess the capacity to prevent the activation of AIM2 
during infection of DCs. A very recent report implicated a critical role of AIM2 in Mtb 
infections [221]. In vivo, mice deficient in Aim2 were highly susceptible to Mtb infections. 
In vitro, Aim2 deficient peritoneal macrophages infected with Mtb or transfected with Mtb 
DNA were shown to have defective caspase-1 activation and impaired IL-1β secretion 
[221]. Our findings disagree with these in vitro reports [221]. However, it is important to 
note that our analysis was done in dendritic cells and not macrophages suggesting that the 
AIM2-dependent Mtb-induced IL-1β production depends on the type of host cells.  
The activation of AIM2 inflammasome requires sensing of bacterial dsDNA in the 
cytoplasm [211] suggesting that mycobacterial DNA should be released in the cytosol of 
infected cells in order to mount an AIM2-dependent IL-1β secretion. Mtb resides within 
phagosomes of host macrophages and DCs. The escape of mycobacteria from the 
phagosome into the cytosol of infected cells has been a subject of debate for many years 
since translocation of Mtb into the cytosol has been observed by several groups [263], 
[264], while other groups failed to observe such a phenotype [264]. M. marinum has been 
shown to escape from the phagosome into the cytoplasm via actin-based motility, which 
depends on the region of difference 1 (RD1) [264]. Mtb and M. leprae were also shown to 
escape the phagosome and translocate into the cytoplasm of myeloid cells in a RD1-
dependent fashion [264]. Our results support the hypothesis that Mtb does not translocate to 
the cytosol of DCs since Mtb infection of BMDCs did not lead to the activation of the 
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AIM2 inflammasome (Figure 22), which is activated by cytosolic bacterial dsDNA. 
However, attenuated Mtb H37Ra as well facultative pathogenic Mkan and non-pathogenic 
Msme and Mfort were able to induce the secretion of IL-1β via AIM2-dependent pathway 
(Figure 22) suggesting that these mycobacterial strains can somehow escape to the 
cytoplasm or have their DNA exposed in the cytosol of host DCs and interact with AIM2. 
It is therefore interesting to determine how mycobacterial DNA becomes exposed in the 
cytoplasm of host cells and is sensed by AIM2.  
The activation of AIM2 inflammasome was shown to be dependent on IFN-β in 
macrophages and partially dependent on IFN-β in DCs [217]. IFN-β has been suggested to 
act upstream of AIM2 [221]. First, the sensing of bacteria in the cytoplasm via an 
unidentified process leads to the secretion of IFN-β and type I interferon receptor (IFNR) 
signaling. Second, the recognition of bacteria in the cytoplasm via a PRR that leads to 
activation of the inflammasome and subsequent IL-1β processing if the first signal from the 
IFNR was received [260]. Our assessment of the involvement of IFN-β in AIM2-dependent 
mycobacteria-induced IL-1β secretion demonstrated that IFN-β plays an important role in 
the AIM2-dependent secretion of IL-1β in Msme-infected but not Mtb-infected DCs. Our 
results showing that blocking of IFN-β in Msme-infected BMDCs results in a decreased 
secretion of IL-1β (Figure 23) support the hypothesis that Msme induces secretion of IFN-β 
in DCs.  IFN-β was reported to increase AIM2 protein levels and inflammasome activity in 
response to Francisella infection [258]. However, it is important to note that this IFN-
β/AIM2 inflammasome activation is not the only inflammasome pathway leading to the 
production of IL-1β since Msme still induces the secretion of mature IL-1β in DCs via 
NLP3-dependent pathway as we have demonstrated. 
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CHAPTER 4. SUMMARY AND FUTURE DIRECTIONS 
 Non-pathogenic mycobacteria are strongly attenuated and do not cause 
disseminating disease even in immunocompromised individuals [59]. We hypothesized that 
this attenuation is due to their capacity to induce a strong innate IR via induction of 
apoptosis and proinflammatory cytokine secretion in host cells. Our results demonstrated 
that non-pathogenic mycobacterial species Msme and Mfort induce rapid and elevated host 
cell apoptosis, as well as increased TNF and IL-12 secretion levels seen in host 
macrophages and DCs compared to facultative pathogenic BCG and Mkan. We have 
characterized this apoptotic response as dependent on TNF and caspase-3 signaling 
pathways in addition to being dependent on the host’s genotype; only BALB/c, but not 
C57Bl/6, macrophages showed increased apoptosis when infected with non-pathogenic 
mycobacteria. The comparison of macrophages to DCs revealed that the apoptotic response 
in the latter is stronger upon infection with non-pathogenic mycobacteria. Our finding that 
non-pathogenic Msme induced the accumulation of high levels of ROS only in the 
phagosome of infected DCs, but not macrophages, supported the hypothesis that DCs are 
more susceptible to infection-induced apoptosis. This may be due to their capacity to 
generate high levels of ROS, which can lead to a sustained JNK activation and shift the 
TNF signaling pathway towards cell death via apoptosis [163]. Research in our lab has 
shown that the accumulation of ROS in DCs, but not macrophages, was reported to be due 
to NOX2 activity in DCs that is sustained compared to the rapid induction and inactivation 
of NOX2 in macrophages [163]. We have also shown in published data that the cell wall 
component PI-LAM, purified from non-pathogenic Msme and Mfort, induced increased 
inflammatory cytokine secretion and apoptosis response when compared to Man-LAM of 
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facultative-pathogenic mycobacteria [71]. 
Based on our findings, we propose that the different mycobacterial species can be 
organized into the following three functional groups: 1) Nonpathogenic mycobacteria that 
have no mechanisms to inhibit the host IR and have a multitude of mechanisms to induce a 
strong host IR, 2) facultative-pathogenic mycobacteria that have few if any mechanisms to 
inhibit host cell IR but have evolved to mask some of their PAMPs so they do not induce a 
strong innate IR, and finally 3) highly adapted virulent mycobacteria that can mask their 
PAMPs and have mechanisms to inhibit host immune responses. We therefore hypothesize 
that mycobacteria in the non-pathogenic functional group possess genes involved in the 
production and modification of PAMPs that interact with the host’s PRRs leading to the 
induction of a strong IR. For future directions, we propose an experimental strategy to 
identify new genes in the non-pathogenic Msme that are involved in the production and/or 
modification of PAMPs. This analysis would involve the construction of a transposon 
mutants library in Msme and then screening of this library for mutants that are defective in 
the induction of innate IR. We propose to mass infect THP-1 cells with the Msme 
transposon mutants and screen for mutants that are defective in their capacity to induce 
rapid host cell apoptosis. We would then test individual screened mutants for their ability to 
induce apoptosis in BMDMs and BMDCs. Once identified, the genomic DNA of these 
mutants would be isolated, digested, transformed into E. coli, and sequenced for the 
determination of the site of transposon insertion and identification of the gene of interest. 
Once identified, the gene(s) of interest would be transformed into the mutant Msme for 
complementation. We would then use the mutant, the complemented, and the WT Msme 
strains to characterize the gene product’s location via myc tagging and analysis of 
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subcellular fractions and culture filtrates. We also propose to test the viability of the 
mutant(s) in vitro and in vivo by infecting BMDMs and BMDCs as well as SCID mice, 
respectively, followed by organ histopathology and detection of host cell apoptosis. 
In addition, our analysis of the induction of inflammasome activation and IL-1β 
secretion in macrophages and DCs demonstrated that the Msme-induced IL-1β secretion in 
DCs is dependent on ASC but partially independent of NLRP3 and casapses-1/11. This 
caspsae-1/11- partially independent IL-1β secretion was also shown in Msme-infected 
macrophages. Further analysis of the Msme-induced IL-1β secretion revealed that this 
secretion is independent of caspases-3, -8, -9, as well as cathepsins (B, S, and L), calpain, 
and dectin-1. Nevertheless, we demonstrated that the secretion of IL-1β in Msme-infected 
BMDCs involves a caspase(s) other than caspase-1 as the treatment of Il-1β-/- Msme-
infected BMDCs with a general caspase inhibitor further decreased the secretion of IL-1β. 
A recent study has implicated the involvement of caspase-8 and dectin-1 in the secretion of 
IL-1β independently of inflammasome activation in macrophages and DCs [255]. 
Conversely, our analysis did not agree with these reports and caspase-8 was not shown to 
be involved in the secretion of IL-1β in infected BMDCs. It is therefore important to 
identify the potential caspase(s) involved in the secretion of the cytokine. As future 
directions we propose to use a siRNA approach to knockdown several individual caspases 
such as caspase-2 and caspase-10 in BMDCs and check the effect of their silencing on the 
secretion of Msme-induced IL-1β secretion.  
Our results also implicated, for the first time, the involvement of the AIM2 
inflammasome in the secretion of IL-1β in mycobacteria-infected DCs. Our comparative 
analysis of a wide range of mycobacterial species demonstrated that only non-pathogenic 
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and attenuated mycobacterial species but not virulent Mtb involve AIM2 in the secretion of 
IL-1β in DCs. It is reported that AIM2 regulates caspase-1 activation and IL-1β secretion in 
response to dsDNA from a variety of viruses, bacteria, and even from the host [211]. The 
activation of AIM2 inflammasome requires sensing of bacterial dsDNA in the cytoplasm 
[211] suggesting that mycobacterial DNA should be released in the cytosol of infected cells 
in order to mount an AIM2-dependent IL-1β secretion. Despite the contradicting reports 
about the ability of mycobacteria to escape from the phagosome into the cytosol of host 
cells [263] [264], there has been no clear evidence that Mtb and Msme can escape into the 
cytosol. It is therefore important to understand how non-pathogenic and attenuated 
mycobacteria can activate the AIM2 inflammasome. We propose, as future directions, to 
check for the presence of mycobacteria and mycobacterial DNA in the cytosol as well as 
their proximity to AIM2 proteins of infected cells. For this purpose we propose to use 
immunofluorescence confocal microscopy of BMDCs infected with Msme and stained with 
antibodies detecting endogenous AIM2 and Msme in the cytosol. We would also pre-label 
Msme and virulent Mtb with Hoechst 33342 nucleic acid stain and use them to infect 
BMDCs in order to visualize the spatial localization of mycobacterial DNA and AIM2 via 
fluorescence microscopy. We would expect Msme but not virulent Mtb remnants and/or 
DNA to colocalize with AIM2 in the cytosol. Such results would provide one explanation 
for the capacity of Msme to activate the AIM2 inflammasome, in contrast to virulent Mtb, 
which is not able to do so.  
We also characterized the AIM2-dependent IL-1β secretion as dependent on IFN-β, 
which was reported to be important for the Francisella-induced AIM2 activation and IL-1β 
secretion in macrophages and DCs [217] [258]. Our results showing that blocking of IFN-β 
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in Msme-infected BMDCs results in a decreased secretion of IL-1β (Figure 23) support the 
hypothesis that Msme strongly induces the secretion of IFN-β in DCs compared to virulent 
Mtb, which does not induce such cytokine secretion.  IFN-β was reported to increase AIM2 
protein levels and inflammasome activity in response to Francisella infection [258]. 
However, it is important to note that this IFN-β/AIM2 inflammasome activation is not the 
only inflammasome pathway leading to the production of IL-1β since Msme still induces 
the secretion of mature IL-1β in DCs via NLP3-dependent pathway. To further test this 
hypothesis, we propose, as future directions, to check the levels of IFN-β secreted by 
BMDCs upon infection with the wide range of non-pathogenic, attenuated, and virulent 
mycobacterial species like in Figure 23. We would expect the non-pathogenic and 
attenuated mycobacteria, but not virulent Mtb, to induce the secretion of large amounts of 
IFN-β by host DCs. Such results would provide one explanation for the capacity of virulent 
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